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Abstract
Diabetes mellitus is a leading cause of morbidity and mortality worldwide, and close
monitoring of blood glucose levels is crucial for its diagnosis and management. Cur-
rently, blood glucose monitoring is done by blood withdrawal or through invasive
access to the interstitial fluid. While Raman spectroscopy has been studied as a
possible non-invasive optical technique for measuring blood glucose, it still faces sev-
eral practical difficulties. These include tissue turbidity and autofluorescence, the lag
between blood and interstitial fluid glucose concentrations, and the inherently weak
intensity of aqueous glucose Raman signatures with respect to those of the interfering
tissue.
This thesis investigates the feasibility of using Raman spectroscopy as a non-invasive
technique for blood glucose monitoring, and studies different strategies to overcome
the barriers to clinical application. In particular, the study proposes a dynamic con-
centration correction scheme to correct for the calibration errors arising from the
lag between glucose concentrations in the bloodstream and the interstitial fluid. In
addition, Monte Carlo simulations were employed to study the differences in the
distribution of Raman scattered photons along the depth of the tissue between back-
scattered and transmission mode Raman spectroscopy. Finally, a portable clinical Ra-
man spectroscopy unit was developed utilizing a non-imaging optical element called a
compound hyperbolic concentrator (CHC). The CHC coupled with a matching focus-
ing lens efficiently collects and collimates Raman light from highly scattering tissues,
while maintaining much smaller physical dimensions than a compound parabolic con-
centrator.
Using the clinical instrument, skin Raman spectra were collected from healthy hu-
man subjects undergoing oral glucose tolerance tests, while the corresponding refer-
ence blood glucose concentrations were measured simultaneously with a conventional
finger-stick glucose meter. From these datasets, linear and non-linear multivariate cal-
ibration techniques were used to relate the Raman spectral intensities to the glucose
concentrations. The calibrated algorithms were then tested to demonstrate clinical
accuracy as required by the Food and Drug Administration and the International
Organization for Standardization. Despite the remaining challenges, the promising
results obtained in this study provide important insights required in the clinical trans-
lation of Raman spectroscopy for non-invasive blood glucose monitoring.
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Chapter 1
Introduction
Diabetes mellitus is a debilitating disease characterized by the impaired blood glucose
regulation, and it continues to affect increasing number of people worldwide. A close
monitoring of blood glucose level is essential for effective diagnosis and management
of the disease, but currently this is achieved by frequent blood withdrawal and other
invasive methods. This is not only inconvenient for most diabetics, but also presents
tremendous difficulties to individuals with needle phobia and Type I diabetic children.
Clearly, a non-invasive glucose monitoring technique would significantly improve the
patients' quality of life, as well as compliance to glucose monitoring.
Raman spectroscopy has been studied as a promising candidate for non-invasive
optical blood glucose measuring technique. During a Raman event, the inelastic
scattering causes the incident photon to lose energy by the amount specific to the
particular vibrational and rotational modes of the interacting molecule. As such, the
resulting Raman spectrum provide exceptional chemical specificity. In addition, since
the intensity of Raman spectrum is proportional to the concentration of the interact-
ing molecule, analyzing the aggregate Raman spectrum by multivariate calibration
techniques allows for an accurate quantification of the individual chemical compo-
nents. Many laboratory based, proof-of-principle experiments have been performed
to demonstrate the potential of Raman spectroscopy to accurately measure blood
glucose concentrations in a non-invasive manner.
However, transdermal glucose measurement by Raman spectroscopy is yet to be
seen in the daily clinical setting due to many remaining practical challenges. For
example, the non-invasive nature of transdermal Raman spectra collection precludes
direct measurement of blood glucose and this limits the optical tissue sampling vol-
ume to the interstitial fluid (ISF) space. While the blood glucose concentration is
the clinically relevant parameter, the ISF glucose level as measured by non-invasive
Raman spectroscopy is an indirect indicator for blood glucose. This leads to com-
plications in calibration steps during rapid changes in glucose levels, such as after a
meal or insulin administration, due to the time lag between the blood and interstitial
fluid glucose concentrations during these non-equilibrium states. In addition, sponta-
neous Raman scattering is an inherently weak phenomenon, and collection of Raman
spectra from humans in a clinical setting requires specially designed high-throughput
spectroscopic instruments that are also compact enough to be portable. Previous
human subject studies for glucose detection have mainly been conducted using a sta-
tionary laboratory-based Raman spectroscopy setup.
This thesis aims to demonstrate the clinical feasibility of accurate and non-invasive
glucose concentration measurements by Raman spectroscopy on a population of hu-
man subjects. For this purpose, a high throughput and portable clinical Raman
spectroscopy system is designed and constructed. In addition, potential solutions are
provided for the aforementioned challenges.
1.1 Objectives
1.1.1 Address the issue of lag between blood and ISF glucose
concentrations
The effect of the lag between blood and ISF glucose concentrations on the spectro-
scopic calibration and prediction performance had to be characterized. Based on the
insight provided by this analysis, a potential solution to the problem needed to be
presented.
1.1.2 Design and construct a high-throughput and portable
clinical Raman spectroscopy system
This objective required satisfying two seemingly conflicting goals of achieving high
throughput while maintaining compactness for practical clinical application. Previous
laboratory-based Raman spectroscopy setups had to be studied in order to identify
the targets of optimization, while new non-imaging optical elements were to be in-
vestigated for their potential to enhance light collection efficiency. In addition, the
implications of collecting tissue Raman spectra in the transmission mode had to be
investigated.
1.1.3 Demonstrate clinical feasibility through human subject
studies
The completed clinical instrument was to be used for collecting Raman spectra from
human subjects in a clinical setting. The collected Raman spectroscopy and blood
glucose data were to be analyzed to determine the glucose measurement performance
and clinical feasibility.
1.2 Major accomplishments
* The problem of the time lag between blood and ISF glucose concentrations was
investigated and a viable solution has been developed. The new calibration
scheme was termed "dynamic concentration correction" (DCC) which showed
significant improvement in spectroscopic calibration and glucose prediction per-
formance during rapid changes in glucose levels.
* A high throughput and portable clinical Raman spectroscopy instrument has
been designed and constructed using a compound hyperbolic concentrator (CHC).
The distribution of Raman scattering events along the depth of the skin tis-
sue was simulated by Monte Carlo methods for both back-scattered mode and
transmission mode. The simulation studies revealed potential advantages of
transmission geometry over back-scattered mode.
o The clinical instrument was used successfully for collecting Raman spectra from
human subjects undergoing OGTT. Different calibration and prediction schemes
were used on the same data to compare their relative performance. The analysis
of the clinical data indicated that when used for the measurement of glucose
concentrations on the same skin tissue site under identical measurement condi-
tions, the performance of the Raman spectroscopy instrument was good enough
to meet the requirements of the U.S. Food and Drug Administration as well
as the International Organization for Standardization. However, the study also
revealed potential difficulties arising from the change in measurement site and
conditions.
1.3 Thesis outline
1.3.1 Chapter 2 Background and significance
This chapter describes the prevalence and types of diabetes and motivates the need
for a non-invasive glucose monitoring technique. It also reviews other minimally
invasive and non-invasive glucose monitoring techniques, and introduces NIR Raman
spectroscopy as a promising candidate while emphasizing its advantages over other
techniques.
1.3.2 Chapter 3 Correcting for the lag between blood and
interstitial fluid glucose
This chapter describes the presence of the lag between blood and interstitial fluid
glucose concentrations during rapid changes in glucose levels, and how it affects spec-
troscopic calibration and prediction accuracy, as well as the uncertainty in the pre-
dicted glucose concentration. Then DCC was derived and presented as a potential
solution to this problem, and a new expression was derived to describe the prediction
uncertainty under DCC implementation.
1.3.3 Chapter 4 Monte Carlo study of transmission mode
Raman spectroscopy
In this chapter, a numerical simulation study was designed and performed to gain
a better understanding of the differences between Raman spectra collected in back-
scattered mode and transmission mode geometries. Particular emphasis was placed
on observing the distribution of the Raman scattering events along the depth of the
tissue, under the two different collection geometries.
1.3.4 Chapter 5 Development of clinical Raman spectroscopy
instrument
This chapter elaborates the design and construction of a portable clinical Raman
spectroscopy instrument. In particular, the purpose and the design of the non-imaging
optical element, CHC, was described in detail. The clinical instrument shown in this
chapter was used in the human subject studies described in Chapter 6.
1.3.5 Chapter 6 Human clinical study
This chapter describes the human subject study conducted at the MIT Clinical Re-
search Center (MIT CRC) using the clinical instrument shown in Chapter 5. The
Raman spectra and blood glucose concentration values were used to create calibra-
tion models by partial least squares (PLS) regression and support vector regression
(SVR). Also, the effect of implementing DCC and removing tissue autofluorescence
in the Raman spectra by low order polynomial fitting was observed when performing
glucose calibration and prediction analyses.
1.3.6 Chapter 7 Conclusion and future directions
In this chapter, the objectives and major accomplishments were reviewed. Potential
future directions are suggested based on the new insights obtained from this study.
Chapter 2
Background and significance
2.1 Diabetes mellitus
Diabetes mellitus represents a leading cause of morbidity and mortality worldwide,
affecting nearly 285 million people in 2010, and expected to affect 438 million by
2030 [1]. In 2010 alone, 4 million people died from diabetes worldwide [1]. Diabetes
is characterized by an impairment of blood glucose regulation. In Type I diabetes, a
pathology in the pancreas causes insufficient production of insulin, which is normally
secreted in response to high blood glucose levels in order to promote glucose uptake
by the tissues. These patients typically require external administration of insulin
for proper blood glucose management. Type II diabetes is caused by the body's re-
duced sensitivity to insulin, usually arising as a complication of obesity [2]. Finally,
gestational diabetes can occur in pregnant women who were not diabetic prior to
the pregnancy. While gestational diabetes normally resolves with the end of preg-
nancy, in some cases it may have adverse effects on the fetus such as macrosomia,
in which the baby becomes overweight due to abnormally high blood glucose levels.
Prolonged exposure to high levels of blood glucose accompanies many morbid com-
plications such as blindness and a variety of neurovascular diseases. Therefore, it is
essential to frequently monitor the blood glucose levels for successful management of
the disease. Currently, blood glucose monitoring is achieved by frequent withdrawal
of blood or other invasive means. Due to the inconvenience and invasiveness of these
methods, many diabetics fail to comply with glucose monitoring. In particular, at
least 10% of the U.S. population is affected by needle phobia that can trigger fainting
episodes with needle piercing [3], and needle-phobic individuals who are also diabetic
have extreme difficulty in managing their conditions [4]. Therefore, a non-invasive
method of measuring blood glucose level would greatly benefit the increasing number
of diabetics worldwide.
2.2 Non-invasive and minimally-invasive glucose
monitoring techniques
Most electrochemical glucose sensors currently used in the clinic employs the glucose
oxidase enzymatic reaction:
#-D-glucose+0 2 -+ D-glucono-1,5-lactone + H202
where gluconic acid and hydrogen peroxide (H202) are generated. The hydrogen
peroxide can then be detected with a platinum electrode. These sensors have been
adapted in the form of a needle, which can be implanted subcutaneously for continu-
ous glucose monitoring (e.g., Minimed by Medtronic Inc. and FreeStyle Navigator by
Abbott Laboratories). However, these minimally invasive sensors need to be replaced
about once a week due to build up of biomaterial residues on the sensor surface,
which interferes with glucose measurement. Another commercial continuous glucose
monitoring device, the GlucoWatch by Animas, used reverse iontophoresis to ex-
tract interstitial fluid from the skin tissue and measured glucose with electrochemical
sensors [5]. However, this sensor faced practical problems of frequent disruption in
glucose sensing by sweating, and is no longer in production.
Many researchers have looked into optical techniques for non-invasive glucose de-
tection [6]. For example, Esenaliev et al. proposed the use of optical coherence
tomography for glucose detection, by observing the variation of tissue optical scatter-
ing parameter (p-,) induced by changes in the glucose concentration [7]. The optical
scattering coefficient j, and the reduced scattering coefficient p' depend on the mis-
match of the refractive index of the interstitial fluid (1.348 to 1.352 in near infrared
[8]) and the cell membranes (1.350 to 1.460 in near infrared [9]). Change in the
blood glucose concentration would alter the interstitial fluid glucose concentration,
which would subsequently affect the refractive index and the optical scattering pa-
rameters. This effect was demonstrated in tissue phantoms [10] as well as in vivo
using reflectance measurement systems [11].
King et al. suggested that glucose concentration can be measured by observing
the changes in light polarization in the aqueous humor of the eye [12]. When a linearly
polarized light interacts with a solution containing molecules that have a distinct chi-
rality due to its asymmetric molecular structure, the plane of the linearly polarized
light undergoes rotation about the axis of propagation. Since glucose molecules are
chiral (the naturally occurring D-glucose being dextrarotatory), the amount of rota-
tion of the linearly polarized light depends on the concentration of glucose present
in the tissue. However, this effect is difficult to observe in typical turbid tissues,
since the scattering effects dominate over polarization effects. Therefore, King et al.
suggested the observation of light polarization change by shining a linearly polarized
light to the anterior chamber of aqueous humor of the eye, which is a transparent
tissue with little turbidity.
Others have studied changes in the photoacoustic effect induced by different glu-
cose concentrations [13, 14]. The photoacoustic effect measures the optically gener-
ated acoustic signal, where a laser pulse fired onto the tissue sample gets absorbed
and heats up the illuminated region, which thermally expands to generate an acoustic
pressure wave that can be detected with a piezoelectric sensor. Since the viscosity of
aqueous glucose solution increases with glucose concentration, the photoacoustic sig-
nal would also change due to the changes in tissue glucose concentrations. Measuring
and analyzing the changes in the photoacoustic signal from the tissue could lead to the
detection of changes in glucose concentrations. An in vivo study involving 62 human
subjects using a potentially commercializable Aprise' sensor (Glucon Inc., Boulder,
CO) showed promising results [14]. In addition, Wadamori et al. showed that the
measurable tissue depth can be controlled by changing the modulation frequency [15],
which can be useful for detecting glucose from tissues with layered structures such as
the skin.
Evans et al. [16] investigated the glucose-induced changes in tissue autofluores-
cence mediated by variations of reduced nicotinamide adenine dinucleotide (NADH)
or its phosphorylated derivative, NAD(P)H from glucose metabolism. The produc-
tion of these coenzymes by the skin fibroblasts and adipocytes is mediated by their
glucose metabolism, and their measured autofluorescence intensity and lifetime have
been found to be indirect markers for the extracellular glucose concentration [16].
All of these techniques attempt to find glucose sensitivity by observing the glucose-
induced optical changes that can be detected non-invasively. However, these tech-
niques often face significant challenges from the fact that the glucose-induced optical
changes are not glucose-specific, and can be influenced by other physiological and
anatomical variations.
In contrast, vibrational spectroscopy techniques look for glucose-specific molec-
ular vibrational markers in the observed spectrum. For example, infrared absorp-
tion spectroscopy is widely used in chemistry to study the vibrational modes of the
molecular bonds, such as "stretching", "twisting", and "scissoring" modes. Since
different molecules are uniquely identified by their molecular structures, vibrational
spectroscopy techniques such as infrared absorption spectroscopy and Raman spec-
troscopy provide a molecularly specific marker for the target analyte. Infrared ab-
sorption spectroscopy was employed in the mid-infrared (MIR) region (2.5 to 25 pm)
by Heise et al. to detect glucose from the oral cavity [17], but faced difficulty due
to limited tissue penetration depth of MIR light and person-to-person variations in
MIR absorption spectra. As near infrared (NIR) light (800 nm to 2.5 tm) offers
greater tissue penetration depth and generates relatively low amount of tissue aut-
ofluorescence, many researchers have used NIR absorption spectroscopy to investigate
non-invasive glucose detection from human subjects. Burmeister et al. and Marbach
et al. employed NIR absorption spectroscopy to detect glucose from the oral cavity
[18, 19], while other groups targeted the forearm [20, 21] and fingertip [22, 23]. While
NIR absorption spectroscopy provides molecularly specific information with high op-
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Figure 2-1: Jablonski diagram describing the transition of electronic states for various
spectroscopic modalities.
tical intensities, its broad spectral features often limit its specificity. This was the
main reason behind the failure of Diasensor by Bico, which was a NIR absorption
spectroscopy based glucose monitoring device that was briefly introduced commer-
cially in Europe, only to be abandoned eventually. On the other hand, NIR Raman
spectroscopy provides similar molecular vibrational and rotational information while
also offering much sharper spectral features and superior molecular specificity than
NIR absorption spectroscopy.
2.3 NIR Raman spectroscopy for transdermal glu-
cose detection
Raman spectroscopy can be performed with light at any wavelength, and its spectral
intensity increases with the light frequency to the fourth power. Also, ultraviolet
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Figure 2-2: Raman spectrum of aqueous D-glucose with the molecular vibrational
and rotational modes labeled based on [24].
resonance Raman spectroscopy can provide very high spectral intensities. However,
the NIR spontaneous Stokes Raman spectroscopy is often preferred for biological
tissue analysis, for similar reasons as in the case of NIR absorption spectroscopy:
" Deeper tissue penetration depth.
" Relatively weaker tissue autofluorescence.
" Less photodamage to the tissue.
Unlike NIR absorption spectroscopy, NIR Raman spectroscopy does not suffer from
the adverse effect of NIR light absorption by water. While the large absorption of
NIR light can attenuate tissue NIR absorption spectral features, NIR Raman features
of water are not strong components of the tissue Raman spectrum. The molecular
vibrational and rotational modes of aqueous D-glucose Raman spectrum is shown in
Fig. 2-2. Despite its excellent chemical specificity, the disadvantage of NIR Raman
spectroscopy is that its optical signal is very weak, as typically less than one out of
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Figure 2-3: Spectral calibration and prediction by partial least squares regression.
a million photons undergo a spontaneous Raman scattering event. To make matters
worse for transdermal glucose detection, the Raman cross section of aqueous glucose
is very small (5.6 x 10-30 cm2 molecule- 1 sr-', at 514.5 nm [25]). For this rea-
son, recent studies have suggested the use of surface enhanced Raman spectroscopy
to amplify the glucose sensitivity [26]. Since surface enhanced Raman spectroscopy
alone would amplify all chemical species near the gold or silver substrate, this study
increased the glucose sensitivity by functionalizing the silver substrate surface with
a layer of molecules of high affinity to glucose molecules (specifically, 1-decanethiol
[HS(CH 2)9 CH 3] [26]). Since the Raman surface enhancement effect needs close prox-
imity to the silver or gold substrate surface, the increased glucose affinity of the
functionalized substrate would allow for a selective enhancement of glucose detection
[26].
Early attempts to detect blood glucose concentration by Raman spectroscopy in-
volved a direct analysis of whole blood samples [27, 28]. These studies used partial
least squares (PLS) regression to analyze the blood constituents. Figure 2-3 shows
a schematic diagram describing the PLS calibration and prediction procedures. The
Raman spectral intensities were related to the corresponding reference blood glucose
values by a regression vector called the "b" vector during the calibration procedure.
Once calibrated, the b can be used on a prospective Raman spectrum to extract its
corresponding blood glucose concentration. More advanced and sophisticated cali-
bration techniques were developed later on, in order to improve the robustness and
glucose specificity of the calibration [29, 30]. These include the Hybrid Linear Analysis
(HLA) [29] and Constrained Regularization (CR) [30]. Ideally, if the concentrations
for all constituents of the tissue Raman spectra are known, an explicit calibration
method such as ordinary least squares can be used to construct a comprehensive and
accurate calibration algorithm. However, these explicit calibration methods break
down when the tissue constituents are misrepresented due to lack of accurate infor-
mation about the tissue constituents. On the other hand, implicit calibration methods
such as PLS only require the concentration of the analyte of interest, and therefore
tend to be more robust. Since the Raman spectrum of a pure glucose solution can be
measured separately, HLA attempts to extract the advantages of both explicit and
implicit calibration algorithm, by incorporating the information about the glucose
Raman spectrum into the implicit calibration [29]. This can be done by subtracting
the glucose Raman spectrum (appropriately scaled according to the known glucose
concentration of the calibration samples) from the tissue Raman spectra to remove
the glucose contribution to the overall tissue Raman spectra:
Sb = S - ka (2.1)
where S is the matrix of Raman spectra obtained from the calibration samples, a is
the Raman spectrum of unit concentration of glucose, and k is the concentration of
glucose present in the calibration samples [29]. Then the principal components of Sb
are used to generate a matrix of orthogonal basis spectra V. The residual portion of
a that is orthogonal to V is calculated as:
r = a - aVTV (2.2)
which can be used to obtain the HLA regression vector
b = r/ (a -r). (2.3)
Similarly to HLA, CR performs implicit calibration with explicit constraint specified
by the known glucose Raman spectrum, but it attempts to improve robustness by
employing Tikhonov regularization [31]. Both HLA and CR showed encouraging
results with numerically simulated Raman spectra and tissue phantoms [29, 30].
Eventually, Enejder et al. successfully demonstrated in vivo glucose detection
by collecting Raman spectra from the forearms of human subjects undergoing an
oral glucose tolerance test (OGTT), while Chaiken et al. used tissue modulation on
human finger tip to collect the blood Raman spectrum in vivo, which was subsequently
used to estimate glucose concentration [32]. Here, "tissue modulation" refers to the
measurement of two separate Raman spectra from the same tissue site, with and
without the application of external physical pressure. Applying physical pressure
to the tissue squeezes out the blood and interstitial fluid from the tissue site, while
removing such pressure restores blood and interstitial fluid perfusion. By measuring
the Raman spectra under these two conditions and subtracting one spectrum from
the other, the residual Raman spectrum can (in principle) represent the net signal
arising from the blood and interstitial fluid alone [32]. Since glucose is present in
the blood and interstitial fluid, this tissue modulation method would, if successful,
remove the Raman spectral contributions from the interfering tissue constituents and
improve the glucose specificity.
More recently, Shih et al. and Barman et al. proposed to use the diffuse re-
flectance spectrum to remove the undesirable turbidity-induced Raman spectral in-
tensity variations [33, 34, 35]. In addition, it has been suggested that calibration errors
introduced by spurious correlations between tissue autofluorescence photobleaching
and the glucose concentration can be reduced by applying autofluorescence removal
techniques [36, 37, 38]. Finally, it has been shown that a non-linear regression tech-
nique called support vector regression (SVR) could significantly improve the spectral
calibration and glucose prediction performance over conventional linear partial least
squares (PLS) technique [39].
However, these promising recent developments still do not cover all remaining
issues that need to be resolved before transdermal glucose monitoring by Raman
spectroscopy can become a routine clinical practice. The following chapter describes
the problem of the lag between blood and interstitial fluid glucose concentrations and
presents a potential solution. The later chapters will describe the study of trans-
mission mode Raman spectroscopy, efforts for clinical instrument development, and
the human subject studies conducted to verify the clinical feasibility of transdermal
glucose monitoring by Raman spectroscopy. Finally, the last chapter will discuss
the remaining challenges and suggests potential future directions based on the new
insights obtained from this study.
Chapter 3
Correcting for the lag between
blood and interstitial fluid glucose
3.1 Introduction
From the thick aorta down to the few micron-thick capillary vessels, the blood circu-
latory system permeates most parts of the human body. By the constant pumping
action of the heart, the blood never ceases to transport nutrients and waste products
to and from the living tissues to maintain homeostasis. For this reason, the glucose
metabolism of the entire body can be monitored in the clinic by analyzing the blood
samples withdrawn from the finger tip. However, blood is contained within the cir-
culatory system, and the exchange of nutrients with the surrounding tissues occurs
through the capillary wall by hydrostatic and osmotic pressures, as well as by passive
diffusion. This happens in the fluid that fills the space between the capillaries and
the surrounding cells, which is called the interstitial fluid (ISF). The exchange of
glucose molecules between the blood vessels and the ISF continue until the glucose
concentrations in the two compartments reach equilibrium. This equilibrating process
takes time (typically on the order of 20 minutes in healthy humans), and the time lag
leads to temporary differences between the glucose concentrations in the blood and
the ISF, especially during rapid changes in glucose levels such as immediately after
a meal ingestion or insulin administration. This leads to challenges in non-invasive
and minimally invasive glucose detection techniques, which typically monitor glucose
levels from the ISF. For the case of NIR Raman spectroscopy, the NIR light pene-
trates the skin about 1 mm. At this depth, the blood capillaries are not very dense,
contributing only about 5% of the skin volume, while the ISF constitutes nearly
45% [40, 41]. Therefore, the optical sampling volume mostly comprises of the ISF
glucose. Similarly, minimally invasive electrochemical sensors such as Medtronic Min-
imed Guardian and FreeStyle Navigator from Abbott Diabetes Care are implanted
under the skin to monitor the ISF glucose. In both cases, complications arise from
the fact that reference glucose measurements for calibration are made from blood glu-
cose. As pointed out by Cengiz and Tamborlane [42], the physiological lag introduces
systematic errors during calibration which adversely impact long-term sensor perfor-
mance, even in the presence of a positive correlation between blood and ISF glucose
[43, 44, 45]. Such diagnostic errors may lead to unnecessary insulin administration,
which could lead to a dangerous degree of hypoglycemia. While this calibration er-
ror could be avoided by performing all measurements under equilibrium conditions,
obtaining multiple calibration measurements at different glucose levels would require
employing sophisticated and riskier glucose clamp techniques, where the glucose is
artificially infused into the bloodstream and the infusion rate is carefully controlled
to maintain a steady plasma glucose level [46]. Moreover, even if calibration was done
accurately, the lack of knowledge of glucose kinetics in prediction samples would in-
troduce an uncertainty in the concentration estimates.
In order to account for the differences in blood and ISF glucose, Freeland and
co-workers developed a model where the ISF and blood glucose were considered to
reside in two compartments [47, 48]. By relating the glucose concentrations in the
two compartments with a simple mass transfer model across a semipermeable mem-
brane, accurate estimates of blood glucose concentration could be extracted from
subcutaneous ISF electrochemical sensor measurements. This chapter introduces a
new spectroscopic calibration scheme using dynamic concentration correction (DCC),
which is based on a on a similar two-compartment mass transfer model [4 9 ]t. While
tThe first two authors contributed equally to this cited article, as stated explicitly in its "Ac-
Freeland and co-workers developed the two-compartment mass transfer model to ex-
plain the glucose lag observed in implantable electrochemical glucose sensors, cur-
rently no analogous models exist for spectroscopic calibration algorithms, which are
inherently more complex due to the multivariate nature of the data. By using DCC,
blood and ISF glucose concentrations are interconverted at the appropriate stages of
spectroscopic calibration and prediction to form an accurate and consistent regres-
sion model. The resulting regression model can then be used on a new set of acquired
spectral samples to accurately predict the blood glucose concentrations. In addition,
an analytical expression is derived to describe the limiting uncertainty arising from
the presence of the lag between blood and ISF glucose concentrations.
3.2 Dynamic concentration correction
Conventional spectroscopic calibration methods use linear regression to map the spec-
tral intensities to the glucose concentrations [50], which is represented as a flowchart
in Fig. 3-1. During the calibration step, the regression vector b is obtained by
b = ScibCLOd (3.1)
where Sc,,ib is the matrix of calibration spectra, Sjieb is the appropriate pseudo-inverse
of Scauib as evaluated by the calibration method of choice, and cblood is the vector of
measured reference concentrations of the blood glucose in the calibration samples.
Since the optical spectroscopy measurements are predominantly contributed by ISF
glucose, the relevant input concentrations to the implicit calibration method should
also incorporate the ISF glucose concentrations for consistency. However, blood glu-
cose concentration is the most clinically relevant value and, in a typical clinical set-
ting, blood glucose values are used as reference concentrations since blood sample-
based glucose analysis is currently the most reliable and readily available method of
measurement. This inconsistency creates calibration errors in the regression vector
bconventionai, as it is based on both the blood and ISF glucose concentrations which
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Figure 3-1: Conventional linear regression flowchart. Scalib: the matrix of calibration
spectra, Sliib: a form of inverse matrix of Scoaib, cbswd: vector of measured reference
blood glucose concentrations, bcventionea: regression vector obtained by conventional
linear regression, sped: vector of a prediction spectrum, c: predicted glucose concen-
tration.
may be significantly different during rapid changes in glucose levels.
In the prediction step, the predicted glucose concentration c, is obtained by a
scalar product of the regression vector bcnventiod, and the spectrum acquired from
the prediction sample s,ed as shown in the following equation:
c = sTbcoventional (3.2)
where superscript T denotes the transpose of the vector. Due to the calibration errors
present in the regression vector bcoventiona, the predicted glucose concentration is
reported as the blood glucose concentration c obtained in the above conventional
----- --- -
Figure 3-2: DCC-based linear regression flowchart. PC-DCC: Pre-calibration DCC,
PP-DCC: Post-prediction DCC, Scabib: the matrix of calibration spectra, Smlib: a
form of inverse matrix of Scalib, CboM: vector of reference blood glucose concentrations,
CISF: vector of ISF glucose concentrations, bocc: regression vector obtained by DCC,
s,: vector of a prediction spectrum, ci,,d: predicted blood glucose concentration,
cISF: predicted ISF glucose concentration.
framework is not an accurate representation.
In order to correct for this discrepancy, a new calibration methodology is proposed
in which the concentrations are appropriately changed to conform to the spectral
measurements. Based on a two compartment mass transfer model, the dynamic
concentration correction (DCC) performs transformation of glucose concentrations in
two stages:
* Pre-Calibration DCC (PC-DCC)
Transform the blood glucose concentrations in the calibration data set into
their corresponding ISF values before performing calibration of Eq. 3.1. This
ensures that the regression vector b is solely based on ISF glucose concentra-
tions.
9 Post-Prediction DCC (PP-DCC)
After calibration, estimate the ISF glucose concentration from a prediction
spectrum using Eq. 3.2. Then transform this ISF glucose concentration into
the corresponding blood glucose value.
As conceptually described in the flowchart of Fig. 3-2, the purpose of these conver-
sions is to ensure that the core spectroscopic calibration and prediction steps are done
in a consistent manner where all glucose concentrations pertains to the ISF glucose
concentration. This would reduce the calibration errors arising from the lag between
the glucose concentrations in the two compartments. After the calibration and pre-
diction, the ISF glucose concentration can be converted back into the corresponding
blood glucose value.
In order to convert between blood and ISF glucose concentrations, a model is
developed to describe the glucose transfer across the capillary vessel wall. The blood
capillary wall is single endothelial cell thick, and has very small tight junction pores
(2~80 nm diameter) through which glucose can be transported by osmotic pressure
and passive diffusion across an established concentration gradient [51]. The glucose
transfer rate is affected by several variables, such as the rate of blood flow, rate of
glucose uptake by the surrounding tissue, and capillary permeability which varies in
different anatomical sites. Nevertheless, a simple two-compartment model can be used
to describe the macroscopic picture of glucose transfer across the capillary membrane
[47, 52, 53]. The change in glucose concentrations within the skin ISF volume, VISF,
can be described as follows:
VISF = kM A(CBG - CISF) - kUVISFCISF (3.3)dt
where CISF and CBG are the ISF and blood glucose concentrations (mol/cm3 ), km is the
glucose mass transfer coefficient (cm/s), A is the effective mass transfer surface area
(cm2 ), and ku is the rate of glucose uptake by the neighboring cells (s- 1 ). Although
ku is affected by the amount of insulin present in the bloodstream, it can be assumed
to be constant due to the observed results that the glucose uptake in subcutaneous
skin tissues is largely unaffected by the local insulin concentrations [52, 47]. In fact,
the uptake term itself has been observed to be very small for skin tissues, unlike
muscle or adipose tissues, therefore it has been ignored (ku = 0) in the analysis [47].
With these assumptions, eq. 3.3 can then be simplified to
dcISF (4
CBG = CISF + a d (3.4)
where a(= VISF/(kMA)) is a lumped mass transfer parameter having units of time.
The parameter o provides a measure of the lag time arising from the glucose transport
and from this point it will be referred to as the characteristic lag time constant. By
using eq. 3.4, the blood glucose concentration can be estimated from the spectroscopy-
based ISF glucose concentration and the knowledge of the lag time constant and the
rate of change in glucose levels. This is done during the post-prediction (PP-DCC)
step (Fig. 3-2). In practice, eq. 3.4 needs to be discretized in order to be implemented
in digital computers. A first-order estimate of the blood glucose concentration can
be obtained by using a finite difference approximation for the derivative term of eq.
3.4:
CBG(t) = CISF(t) + a CISF) - CISF(t - At) (3.5)At
where At is the time interval between spectroscopic measurements and ISF glucose
concentration estimates. With this discretized expression, the PP-DCC step can be
performed in real time using digital computers. It can also be seen that at least
two spectroscopic measurements of ISF glucose (at t and at t - At) are required
to determine the blood glucose concentration using eq. 3.5. The time interval of
measurement, At, should be short enough to capture the fastest physiological glu-
cose variations, and it cannot be arbitrarily short as only a limited number of blood
withdrawal is allowed during human oral glucose tolerance tests. Based on the fact
that it could take as short as 20~30 minutes to reach peak glucose levels from fast-
ing level during oral glucose tolerance tests, At was optimized to be 5-10 minutes.
Other research laboratories sample blood glucose at similar time intervals ranging
from 2.5 to 10 min [54, 52, 20]. To determine the values of the concentrations and
their derivatives at intermediate points, spline interpolation can be employed.
In the other portion of the proposed scheme, the pre-calibration DCC (PC-DCC)
step, the glucose concentrations are transformed in the opposite direction, from blood
glucose to ISF glucose. In order to obtain the expression for PC-DCC, the differential
equation of eq. 3.4 can be converted into its integral form:
1 1 0f 1
CISF(tf) = cISF(ti) exp (if - ti) + - cBG eXp - (tf - ti)) dt (3.6)
a a e ti(a
where the definite integral is evaluated from time t2 to time tf. Similar to the PP-
DCC, this integral equation needs to be discretized for practical implementation. This
can be achieved by performing integration by parts for the second term of eq. 3.6 and
using a numerical integration technique called Simpson's rule to obtain the following
equation:
CISF(tf) = CBG (tf ) + (cISF (ti) - CBG(ti)) exp (- ti) - 6 A (3.7)
a, 6
where
A = BG (ti) eXp -tf ti + 4 0BG exp t- t) + BG (tf) (3-8)
a )( 2 2a)
Here, BG(t) refers to the derivative of CBG evaluated at t. A first-order finite
difference approximation similar to that employed in eq. 3.5 for the PP-DCC step
can be used to approximate dBG(t). One complication with this formulation is that
the initial ISF glucose value CISF(0) needs to be determined for the very first time
window [tj = 0, tf]. This initial condition can be determined accurately when the
ISF glucose and blood glucose concentrations are completely in equilibrium at the
beginning of the spectroscopic calibration measurements. Under such conditions,
cISF(0) is determined by steady-state approximation Of cBG(0) = CISF(0) (which
assumes zero glucose uptake by the skin connective tissue as in eq. 3.4). This is
typically the case because oral glucose tolerance test (OGTT) protocol requires 8-12
hours of fasting so that the physiological glucose concentration would have stabilized
to the fasting (steady-state) level at the beginning of the spectroscopic calibration
measurements.
3.3 Formulation of prediction uncertainty arising
from physiological lag
The precision of spectroscopy-based calibration models can be quantified by using a
prediction error formula derived by Lorber and Kowalski widely known in the chemo-
metrics field, which describes the error propagation for linear multivariate prediction
algorithms [55]. This formulation was used previously by Sdepanovid et al., to de-
scribe the uncertainty in concentration prediction for the limiting case where the noise
in the calibration spectra is negligible in comparison to that of the prediction spectra
[56]. This is typically the case in most biomedical spectroscopy applications, since
CCD or sensor acquisition times can be much longer during calibration than predic-
tion. Under such conditions, when the signal-to-noise ratio (SNR) of the calibration
spectra is sufficiently high in comparison to that of the prediction spectra, it can
be assumed that a perfectly accurate calibration model can be developed from the
calibration spectra. Uncertainty in the predicted concentrations then arises primar-
ily from the spectral overlap between the analyte of interest (glucose) and the other
interfering tissue constituents, and the measurement noise in the prediction spectra.
Mathematically, this spectroscopic uncertainty for the analyte of interest (glucose) is
given by Ac, [56]:
C = (s ± As)' -b = s' - b ± AsT -b = c ± Ac, (3.9)
where
c- -r (3.10)
S9
Here, As represents the noise in the prediction spectrum s, while C and c are the
estimated and actual analyte concentrations in the prediction sample, respectively.
As the modeling noise is ignored in computation of the limiting uncertainty, b rep-
resents the noise-free regression vector for glucose concentration. o- is a measure of
the noise magnitude in the prediction spectrum, Sg quantifies the signal strength of
glucose spectrum at unit concentration, and r/ indicates the amount of overlap (non-
orthogonality) between glucose spectrum and the other interfering spectral compo-
nents in the tissue, such as proteins, lipids, and water.
However, in addition to this spectroscopic uncertainty, there is an additional el-
ement of prediction uncertainty for transdermal glucose measurements that arises
from the physiological lag between blood and ISF glucose levels. Using similar error
propagation analysis as presented above, the following subsections describe the for-
mulation of the limiting uncertainty in glucose concentration prediction due to the
physiological lag, with and without DCC.
3.3.1 Limiting uncertainty due to physiological lag without
DCC
Considering the effect of physiological lag in skin tissues, eq. 3.9 can be rewritten in
terms of the estimated (aISF) and actual (CISF) ISF glucose concentrations.
CISF = (s ± As)' b = CISF ± Acs (3-11)
Given the correct lag time constant for the prediction sample (a,actuai), the actual
blood glucose concentration CBG can be determined from the actual ISF glucose con-
centration CISF using eq. 3.4, on the basis of the blood and ISF two-compartment
model. The value of the actual ISF glucose concentration from eq. 3.11 can be
substituted into eq. 3.4 to give
dcISF d^ISF
CBG = CISF ± -actual = UISF + actual dt ± Acs (3.12)dt d
Without DCC, the estimated ISF glucose concentration CISF is reported in the con-
ventional model as the blood glucose concentration cBG:
CBG = CISF (3.13)
Substituting eq. 3.13 into eq. 3.12 and rearranging, gives
dcISF
CBG = CBG - aactual Ac8  (3.14)
This implies that, without DCC, the limiting uncertainty in the concentration esti-
mate under the conventional calibration method has two separate contributions:
1. The uncertainty resulting from the measurement noise in the prediction spec-
trum and the spectral overlap, Ac,
2. The uncertainty due to the glucose physiological lag, Accom =actuai
While the first uncertainty was well-characterized by Sdepanovid et al. [56], the latter
uncertainty is has not been examined before.
Figure 3-3 illustrates the two contributing factors of the prediction uncertainty.
In this figure, the simulated blood and ISF glucose data in panel A (which mimics
the glucose profiles obtained from an oral glucose tolerance test) are plotted against
each other to produce the solid curves in panel B. The uncertainty due to the noise
and spectral overlap in the prediction spectrum is marked as Ac,. It is evident that
the physiological lag between the blood and ISF glucose profiles in (A) introduces a
hysteresis-like closed loop behavior when blood glucose is plotted against ISF glucose,
showing the lack of a one-to-one correspondence between the glucose concentrations
in the two compartments. When the glucose levels are increasing, the blood glucose
concentrations are greater than the corresponding ISF glucose concentrations (labeled
RISE). Similarly, the set of values obtained during the falling phase is represented by
the concave downward curve (labeled FALL). Specifically, it is observed that, given
an ISF concentration of 148 mg/dL at point P, the actual blood glucose concentration
could be either 132 mg/dL (Q) or 158 mg/dL (T). However, conventional methods
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Figure 3-3: Uncertainty in glucose prediction due to physiological lag. (A) Schematic
representation of blood and ISF glucose concentration profiles, similar to those ob-
tained during a typical glucose tolerance test. (B) ISF and blood glucose concentra-
tions shown in panel A plotted against each other. The solid curve shows the actual
ISF and blood glucose relationship, while the dotted curves represent the deviations
from actual values due to noise and spectral overlap. Without the knowledge about
the glucose dynamics, it cannot be determined whether the blood glucose concentra-
tion lies at point Q or T, for a given 1SF glucose concentration at point P. With the
knowledge about whether the glucose level is rising or falling, the uncertainty in the
estimation of the blood glucose concentrations is significantly reduced.
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without the knowledge about the glucose dynamics would predict, for example, 148
mg/dL (R), giving rise to a significant error in prediction Acc,,, as marked by the
distance between points Q and R.
3.3.2 Limiting uncertainty due to physiological lag with DCC
Unlike the conventional model, the DCC method explicitly accounts for the physio-
logical glucose dynamics. Specifically, the post-prediction equation (PP-DCC) is used
to transform the spectroscopy-based ISF glucose estimate ( ISF) to a corresponding
blood glucose value (CBG), and this step needs to be considered in evaluating the limit-
ing uncertainty. As the correct lag time constant in the prediction sample is unknown
in a real clinical setting, some uncertainty due to the physiological lag is introduced
via the PP-DCC step. Similar to the previous subsection, the aggregate average of
the lag time constants obtained from the calibration samples is used to approximate
the actual lag time constant in the prediction sample. With this approximation, the
PP- DCC equation can be rewritten as
daISF
CBG = CISF - -calib dt3.15)
where dcaib refers to the average value of a computed from the calibration samples.
Substituting eq. 3.11 into eq. 3.15 gives
B ± dcISF6BG = CISF ± ACs -|acalib dt3-1)
The deviation of dealib from the actual lag time constant in the prediction sample,
aactual, can be written as
Ocalib = 0 actual ± Aa (3.17)
where Aa is the error (uncertainty) in the estimation of the lag time constant. Sub-
stituting eq. 3.17 into eq. 3.16 and rewriting the first term of the above equation as
CBG gives
BG = CBG ± Aa ISF 8)dt
Equation 3.18 implies that the net uncertainty is a combination of the uncertain-
ties arising from the spectral noise and overlap (Ac.) and the physiological lag
(AcDCC=Aa-ec ), which is analogous to eq. 3.14 for the case without DCC. How-
ever, the magnitude of uncertainty introduced due to the physiological lag is much
greater for the case without DCC. The lag uncertainty for the conventional calibration
model case without DCC is proportional to tucat, while that for the case with DCC
is proportional to Aa. This can be seen in Fig. 3-3B. In this figure, the dashed curves
connect the points whose coordinates are given by the blood and ISF glucose concen-
trations estimated by the model, in contrast to the solid curve that represents actual
blood and ISF glucose concentrations. Since the exact value of the lag time constant
a is not known, the estimated blood glucose concentrations will differ from the actual
blood glucose concentrations by the product of the rate of change in the glucose con-
centration and the estimation uncertainty of the lag time ACDCC = Aadt-. The
dashed (DCC-estimated) curve is computed using eq. 3.15, whereas the blood and
ISF glucose concentrations (solid) curve are related by eq. 3.4. In Fig. 3-3, it can
be seen that AcDCC (the distance between Q and S), is substantially smaller than
Acc , (the distance between Q and R), as long as the lag time constant a used in
the DCC model is a reasonable approximation of the actual lag time constant.
3.4 Materials and methods
Numerical simulations and data analysis were performed to study the effect of DCC
on glucose measurement performance by the calibration model, and to estimate the
lag time constant a in a human population. For the numerical simulations, ISF
and blood glucose concentration data sets described by Steil et al.[52] were used to
generate tissue Raman spectra for calibration and prediction. The simulations were
also used to understand the relationship between the SNR in the spectral data set
and performance of the conventional and DCC calibration models. To investigate
the lag time distribution in a human population, data sets obtained from previous
clinical studies on human volunteers were employed [57]. In addition, the prediction
uncertainty due to the physiological lag was characterized.
3.4.1 Implementation of DCC on simulated Raman spectra
Steil and co-workers monitored blood and ISF glucose concentrations in non-diabetic
human subjects during glucose clamping [52]. Glucose clamping is a clinical study
procedure developed by Andres and Tobin in which glucose is infused into the human
subject at a variable rate (either with or without insulin infusion) in a controlled
manner to maintain a constant level of blood glucose levels [46]. Although the glucose
clamping technique was originally developed to observe the patient's sensitivity to
insulin as well as the capacity to secrete insulin [46], the technique is also useful for
artificially "clamping" the blood glucose concentration at the desired level. In the
study by Steil et al., after 10-12 hours of overnight fasting, glucose was sequentially
clamped at approximately 5, 4.2, and 3.1 mM (1 mM concentration of glucose e 18
mg/dL) for 90 min each by insulin and glucose infusion and subsequently allowed
to return to normal physiological glucose levels. During this procedure, the ISF
glucose was measured by two MiniMed (Medtronic, Inc.) subcutaneous amperometric
glucose sensors implanted under the abdominal skin. Blood was withdrawn at regular
intervals for blood glucose measurements using a clinical glucose analyzer. From this
clinical study, the blood and ISF glucose concentration data obtained from 90 to 380
min after initial insulin and glucose infusion was used in the numerical simulations
(Fig. 3-4).
This glucose concentration data set was divided into calibration (spanning from
90 to 220 min) and prediction (from 230 to 380 min) sets, respectively. Using the ISF
glucose concentrations, simulated Raman spectra were generated by forming weighted
linear combinations of the constituent Raman spectra of glucose, creatinine, and urea,
which were measured using a Raman spectroscopy setup designed for transdermal
glucose detection [57, 35]. The weight assigned for the Raman spectrum of glucose
was varied as determined by the ISF glucose concentrations of the Steil data set, while
the weights for the remaining tissue consistent spectra were randomly varied within
2% of a constant value, to mimic the minute changes observed in these constituents
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Figure 3-4: Blood and ISF glucose concentration-time profiles measured from a nor-
mal human volunteer during insulin-induced hypoglycemia. Glucose was clamped at
5, 4.2, and 3.1 mM and subsequently allowed to return to normoglycemic levels. It is
observed that the ISF glucose, measured by subcutaneous amperometric sensors, con-
sistently lags behind blood glucose concentrations during both the rising and falling
phases. In contrast, they are equilibrated to nearly identical values during the clamp-
ing phases. Reprinted from ref. [52], Copyright 2005, with permission from Springer
Science and Business Media: Diabetologia.
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Figure 3-5: The same data as Fig. 3-4, with the ISF glucose concentrations plotted
against the corresponding blood glucose concentrations.
during typical glucose tolerance and clamping tests. In addition, to simulate normal
experimental conditions, zero-mean Gaussian white noise was added to the mixture
spectra at varying levels of SNR (20-40 dB) to study its effect on the prediction
performance of the calibration models. In order to optimize the lag time constant a
and the number of loading vectors LV for partial least squares (PLS) linear regression,
an iterative grid-search was performed for the optimal combination of parameters that
produced the smallest calibration error, in the appropriate ranges of a (0 to 20 min)
and LV (2 to 10). Using PC-DCC (eq. 3.6), all but one of the reference blood
glucose concentrations were converted to the corresponding ISF glucose values to
develop a leave-one-out cross-validation calibration model composed purely of ISF
glucose concentrations. The developed calibration model was then used to predict
the ISF glucose concentration at that point. Subsequently, PP-DCC (eq. 3.4) was
used to convert the predicted ISF glucose concentration back into the corresponding
blood glucose value. This process was repeated in a round-robin fashion until all data
points were used once as the validation data. The calibration error was calculated
by comparing the predicted blood glucose concentrations with the reference values to
produce the root-mean-squared error of cross-validation (RMSECV). The resulting
optimal values a4 pt and LVpt that produced the smallest RMSECV were used to
calculate the PLS regression vector bpt. On a separate portion of the data set,
prospective prediction was performed by taking the scalar product of the prediction
spectra with the calibrated bpt (eq. 3.2), producing the ISF glucose predictions.
These ISF glucose values were converted to the blood glucose values using PP-DCC,
where act was used in place of a in eq. 3.4. Then the root-mean-squared error of
prediction (RMSEP) was computed from the predicted blood glucose concentrations
and the reference blood glucose values.
The glucose prediction performance of the DCC-based regression model was then
compared with that of the conventional PLS regression model, as well as a regression
model incorporating a fixed time delay between blood and ISF glucose concentration
profiles. In addition, 20 simulations were carried out at different values of SNR in the
spectral data set (both calibration and prediction) to observe the effect of spectral
noise on the prospective prediction errors.
3.4.2 Implementation of DCC on Raman spectra measured
from human subjects
DCC-based calibration and cross-validation was implemented on clinical data sets
consisting of blood glucose concentrations and skin tissue Raman spectra obtained
from human subjects. The a and LV optimization process described above was used
as a method for estimating the value of the lag time constant in a human population.
Raman spectra were collected from the forearms of healthy Caucasian and Asian
human volunteers undergoing OGTT. The age of the tested human volunteers was
in the range of 21-29, with a mean of 24.5. For the excitation source, an 830 nm
diode laser (Process Instruments) was used at an average power of 300 mW in a 1
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Figure 3-6: Raman spectra and glucose profile during OGTT. (a) Representative
Raman spectra acquired from a human volunteer during OGTT. (b) Blood glucose
concentration profile measured over the same time.
mm 2 spot. An f/1.8 spectrograph (Kaiser Optical Systems) was coupled to a liquid
nitrogen-cooled CCD (1340 x 1300 pixels, Roper Scientific) for spectral dispersion
and acquisition. For each volunteer, OGTT was initiated by the ingestion of a glucose-
rich solution, and Raman spectra were collected every 5 minutes over a 2 hour period.
At the same time, the reference blood glucose concentrations were measured every 10
minutes from blood samples using a clinical glucose analyzer (HemoCue, Inc.), and
spline interpolation was used to correlate the measured blood glucose concentrations
with the spectra collected at intermediate time points. (This study protocol was
approved by the MIT Committee on the Use of Humans as Experimental Subjects.)
Data sets from volunteers exhibiting motion artifacts, inadequate SNR in the acquired
spectra, and impaired glucose tolerance characteristics were excluded from further
analysis.
A representative set of tissue Raman spectra and the corresponding blood glucose
concentration profile acquired from one of the human volunteers are shown in Fig.
3-6. For the selected volunteer data sets, DCC calibration was performed using the
same leave-one-out cross-validation routine as described in the previous subsection.
Iterative grid search was performed on the measured Raman spectra and reference
blood glucose concentrations to determine the optimal value of a and LV for each
individual. In addition, conventional PLS calibration was also performed on the same
data sets to compare the cross-validation errors. The mean and standard deviation
of a determined from the human subjects were used to approximate amtua and Aa,
respectively. These were the estimates of uncertainty due to physiological lag for
the conventional (astsa) and DCC-based (Aa) calibration methods. Finally, these
uncertainty estimates were also compared with the spectroscopic uncertainty, Ac,.
3.5 Results and discussion
3.5.1 Implementation of DCC on simulated Raman spectra
Numerical simulations were used to compare the prospective prediction capability of
the conventional and DCC calibration models. DCC implementation was found to
reduce the RMSECV of the simulated data set from 0.15 mM to 0.04 mM, when the
measured ISF glucose concentrations were used for computing the cross-validation
errors. In comparison, the RMSECV for fixed timed delay PLS processing was com-
puted to be 0.07 mM. These simulation results were obtained for an SNR of 40 dB.
Figure 3-7 shows the measured ISF glucose concentrations plotted together with
cross-validated glucose concentrations from the conventional and DCC calibration
models. It can be seen here that the ISF glucose concentration profile generated with
DCC closely matches the measured ISF glucose concentrations, while that generated
without DCC shows significantly larger deviations. The cross-validation routine also
optimized the lag time constant for the DCC calibration model and the number of
loading vectors for both models. For this data set, the characteristic lag time con-
stant, apt, was determined to be 6.1 minutes, in agreement with the experimentally
observed values of 6-8 minutes [52]. Figure 3-8 shows the results of prospective predic-
tion, in which the measured blood glucose concentration profile is plotted alongside
the prediction profiles, with and without DCC. When the calibration models were
applied prospectively to the prediction data set, the DCC model showed significantly
improved prediction accuracy (RMSEP = 0.14 mM) compared with the conventional
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Figure 3-7: Cross-validation results of conventional (red) and DCC (black) calibration
methods applied to the simulated data set. The measured ISF glucose concentration
values are given by the blue dotted line. In the DCC calibration process, the lag time
constant, aog, was optimized to be 6.1 minutes.
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Figure 3-8: Prospective prediction results of conventional (red) and DCC-based
(black) calibration methods applied to the simulated data set. The measured blood
glucose concentration values are given by the blue dotted line.
PLS scheme (RMSEP = 0.28 mM). In comparison, the simple fixed time delay PLS
processing had an RMSEP of 0.26 mM, which is a slight improvement over conven-
tional PLS implementation, but still significantly poorer than the DCC performance.
From these results, it can be seen that calibration during non-equilibrium conditions
leads to systematic errors, giving rise to much higher prediction errors (Fig. 3-8) than
estimated during cross-validation (Fig. 3-7). In the extreme case, during rapidly ris-
ing and declining glucose concentrations, the presence of such errors could cause the
predicted glucose concentration to have no statistically significant correlation with
the actual glucose concentrations.
The accuracy of blood glucose concentration prediction with and without DCC
was also compared at varying levels of SNR in the spectral data set. Figure 3-9
shows a plot of the RMSEP of blood glucose prediction with conventional and DCC
calibration models as a function of SNR. As expected, an increase in the noise level
corresponded to an increase in error values in both conventional and DCC-based cal-
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Figure 3-9: RMSEP obtained for conventional (red) and DCC (blue) calibration
models, applied to the simulated data set, as a function of increasing SNR. The error
bars represent the standard deviation of RMSEP for 20 iterations.
ibrations. However, under all tested values of SNR, the prediction errors of DCC
calibration models were consistently smaller compared with those of the conventional
PLS models. It was also observed that the mean apt was essentially noise-insensitive,
although the variance from the mean apt were larger for lower SNR (e.g., the standard
deviation in a was computed to be 0.05 and 0.5 minute at 40 and 20 dB, respectively).
From these results, it can be seen that when developing a spectroscopic glucose cal-
ibration model under non-equilibrium conditions, a time series of multiple glucose
measurements are required in order to capture the glucose kinetics. It should also
be noted that applying non-linear or enhanced calibration schemes, such as support
vector machines [58] or hybrid calibration methods [29, 30], alone would not alleviate
inconsistencies in the calibration models as they do not address the lack of one-to-one
correspondence between the ISF and blood glucose concentrations (Fig. 3-3). Nev-
ertheless, when used in conjunction with DCC, such calibration schemes may further
improve the prediction accuracy.
Table 3.1: Cross-validation results of calibration models applied to the human subject
data, with and without DCC.
number with DCC without DCC change in
subject of data a0 ,t RMSECV RMSECV RMSECV
points (min) (mM) (mM) (%)
1 25 9.5 0.87 1.07 19.1
2 26 11.5 0.52 0.72 27.6
3 26 10.5 0.70 0.97 28.6
4 30 11.1 1.02 1.08 5.7
5 25 8.4 0.68 0.79 13.4
6 26 8.4 0.64 0.82 22.0
7 25 7.5 0.72 0.51 17.6
8 29 8.1 0.76 0.87 12.4
9 31 8.3 0.96 1.00 3.4
10 27 12 0.50 0.53 5.3
3.5.2 Implementation of DCC on Raman spectra measured
from human subjects
In real clinical situations, the number of tissue constituents in the skin Raman spectra
are far greater than the simple three constituents (glucose, creatinine, and urea)
employed in simulated Raman spectra described in the previous subsection. However,
even under such challenging conditions, DCC-based calibration methods performed
significantly better than conventional calibration models. Table 3.1 summarizes the
results of leave-one-out cross-validation performed on the data set from each human
subject, using DCC calibration as well as the conventional PLS routine. Here, it can
be observed that application of DCC reduced the RMSECV for the blood glucose
concentration estimates by 15.5% on average, with a maximum decrease of 28.6%.
As mentioned previously in the formulation of DCC, it has been assumed that
the sampling volume of the skin Raman spectroscopy measurement is a subset of the
interstitial fluid space. This assumption was based on the facts that
1. NIR light has a penetration depth of 1 mm in skin tissue.
2. The blood vessels contribute only 5% to the total skin volume [41], with the
outermost epidermis being completely avascular.
However, a small fraction of the inelastically scattered (Raman) light still arises from
the glucose residing in the blood capillaries. While this results in a slight reduction
in the value of the lag time constant, a, the proposed DCC model is sill effective
in improving consistency in the calibration model when the spectral contribution
of blood glucose is small compared to that of ISF glucose, which applies to most
skin Raman spectra. The results also suggest that the value of the lag time constant
(when measured from the same anatomical site) is fairly constant for the tested human
volunteer population. In Table 3.1, the mean of the lag time constant a, 9.5 minutes,
is significantly larger than the standard deviation, 1.6 minute. It should be noted that
in this human subject study, the skin Raman spectra were always measured from the
ventral forearm to minimize the spectral variations arising from different anatomical
sites [57]. The relatively small variation in a indicates that the mean lag time of the
calibration set provides a fairly accurate approximation to the lag time in the ventral
forearm skin of the general human population.
In addition, these results suggest that the physiological lag time constant in hu-
man population can be measured optically [49], using the spectroscopy and analysis
methods described in this chapter. Similar lag time of 10 minutes was also observed
by NIR absorption spectroscopy study performed by Marbach et al. on human lips
[19]. Previous attempts with subcutaneously implantable amperometric sensors have
been observed to have significant lag that is inherent in the sensor electrochemistry,
which obscures the precision of the physiological lag measurements [54]. In addition
to the sensor-specific lag of the subcutaneous amperometric monitors, the difference
in lag time constants observed from the numerical simulations using the Steil data
set (6.1 minutes) and the clinical studies on human volunteers (9.5 i 1.6 minutes)
can be attributed to
1. The difference in the composition of glucose (i.e., the proportion of blood and
ISF) sampled by the spectroscopic and amperometric sensors.
2. The difference in the anatomical sites (abdominal vs. forearm skin) used for
measurements, which may also involve differences in the degree of tissue vascu-
larization.
3. The variations in the population demographics studied in the two studies.
Although changes in blood glucose concentrations typically precede those of the ISF
glucose concentrations, some groups have observed that ISF glucose can fall in advance
of blood glucose during the time of declining glucose levels [59, 60, 61] while the
opposite is true during the rising phase. In such asymmetric situations, a modified
DCC model can be implemented by employing two distinct a values (which may even
be negative) during the rising and falling phases through a piecewise application of
eqs. 3.4 and 3.5.
The mean and standard deviation of a obtained on the human volunteer data set
were also employed in determining the physiological lag uncertainties for the DCC
and conventional calibration methods. For the conventional calibration method, the
uncertainty was calculated as astuaL d-g-, where the mean a of the human volunteers
was used for astua. During rapid increase in glucose levels, the concentration of
glucose in either compartment can change by 2 mg/dL/min (0.11 mM/min) [42].
Using these values, it could be seen that, for the conventional calibration method,
the prediction uncertainty due to lag amounted to approximately 1.1 mM. For the
DCC model, the uncertainty due to lag could be computed by Aadgj, where Aa
was approximated by the standard deviation of a obtained from the human volunteer
data set. Using this value of Aa, the lag uncertainty for the DCC calibration method
was calculated be 0.18 mM. This corresponds to approximately 6-fold reduction in
the lag uncertainty on application of DCC.
As shown previously, eq. 3.10 describes the uncertainty in the spectroscopic glu-
cose concentration measurement arising from the measurement noise in the Raman
spectrum and the spectral overlap between glucose and the interfering tissue con-
stituents [56]. Using tissue phantom Raman spectra measured from a laboratory-
based setup, this spectroscopic uncertainty, Ac., was estimated to be 1.04 mM [35].
Previous studies suggested that this spectroscopic uncertainty would describe the
lowest concentration at which glucose could be detected in the tissue [56]. However,
this does not provide the full picture for the case of transdermal glucose detection, as
it ignores the uncertainty arising from the lag between blood and ISF glucose concen-
trations. When conventional calibration methods were used during rapid changes in
glucose levels, the uncertainty due to lag (1.06 mM) was estimated to be comparable
to the spectroscopic uncertainty (1.04 mM). Therefore, the total uncertainty (2.1 mM)
would be nearly twice as large as the previously accepted value (1.04 mM). On the
other hand, applying the DCC-based calibration method significantly reduces the un-
certainty due to lag, producing a total uncertainty of 1.22 mM, which predominantly
arises from the spectroscopic uncertainty.
3.6 Conclusion
The physiological lag between blood and ISF glucose concentrations creates calibra-
tion errors in conventional spectroscopic calibration methods. The lack of knowledge
of the glucose kinetics also creates additional uncertainty in the estimated glucose
concentration, which is comparable in magnitude to the uncertainty arising from
noise and non-orthogonality in the spectral data. Based on a first order mass transfer
model, the DCC-based calibration method explicitly accounts for the glucose kinetics
and removes the inconsistencies in the calibration and prediction steps. It has been
demonstrated that implementing DCC significantly improves accuracy and reduces
the uncertainty in spectroscopic blood glucose estimation. The resulting improvement
in blood glucose estimates would enhance the ability of Raman spectroscopy to detect
dangerously low blood glucose levels. In addition, by using the information about the
direction and rate of change in glucose concentrations, an impending hypoglycemia
could be detected in a timely manner to initiate preventive intervention. Finally, the
lag time a optimization process outlined in the DCC calibration procedure was able
to estimate the physiological lag time constants from non-diabetic human subjects.
Since it is well-known that inadequate glycemic control causes microvascular and
macrovascular changes [62], repeating the study on diabetic population may reveal
differences in the physiological lag time constants between the two populations.
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Chapter 4
Monte Carlo study of transmission
mode Raman spectroscopy
4.1 Introduction
With the introduction of Raman spectroscopy as a a non-invasive method of analyzing
bulk biological tissues, it became ever more important to consider the implications
of the Raman light excitation and collection geometry. Unlike homogeneous sam-
ples such as purified chemical compounds or crystals, many biological tissue targets
are heterogeneous, and the Raman light excitation and collection geometry radically
affects the shape and size of the optical sampling volume. Depending on the appli-
cation, a specific portion of the tissue may be targeted by varying the Raman light
excitation and collection geometry.
The most commonly used geometry for the collection of tissue Raman spectra is
the back-scattered mode geometry, where the Raman excitation light source and the
collection optics are on the same side of the tissue to collect the Raman scattered
light that returns toward the excitation source. In this configuration, most of the
tissue sampling volume is located near the tissue surface, and a significant amount of
tissue light scattering is required in order for the Raman scattered light to return back
toward the excitation light source. In most biological tissues, the following diffusion
I Epidermis: 0.05 ~1 mm
Dermis: 0.5 ~ 3 mm
Subcutaneous: 1 ~ 100 mm
Figure 4-1: The multiple layers of human skin tissue. The outermost layer is the
epidermis, which is mainly composed of the keratinocytes, melanocytes and the stra-
tum corneum (dead keratinocytes). There are no blood vessels and very little glucose
present in the epidermis. Beneath the epidermis is the dermis, which is mainly com-
posed of fibroblasts, macrophages and adipocytes surrounded by collagen and elastin
matrix. It has very few capillary vessels and the cells are mostly bathed in interstitial
fluid. Further down below, the subcutaneous tissue is mostly composed of adipocytes
and larger blood vessels. The thicknesses of each layer can significantly depending on
the anatomical site.
approximation holds
P > pa
Here, P'u is the effective scattering coefficient defined as
Ps = (1 - gOpS
(4.1)
(4.2)
where t is the scattering coefficient and g is the anisotropy factor which takes on
the value of 0 for completely isotropic scattering, 1 for perfectly forward directed
propagation, and -1 for perfectly backward directed reflection. Although biological
tissues typically have g values between 0.7 and 0.9, eq. 4.1 still holds for most turbid
tissues. With that approximation, the tissue optical penetration depth (1/e intensity
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decay point) can be estimated as [63]
1J = (4.3)
3La (pa + p')
which ranges from 0.5 mm to 4 mm in human tissues for near infrared light [64].
However, this diffusion approximation does not consider the effects of inelastic scat-
tering. It is also not an accurate representation for some tissue types, such as the
human skin epidermis, which (unlike the dermis) requires either an exact solution or
a numerical simulation [65].
A clever modification to the back-scattered mode geometry was introduced by Ma-
tousek et al., where the Raman excitation source and the collection site was separated
by a specific distance in order to control the depth from which Raman scattered pho-
tons were collected [66]. Termed Spatially Offset Raman Spectroscopy (SORS), this
technique uses the fact that the Raman excitation light photons need to travel deeper
into the tissue in order for them to emerge at a greater distance away from the site
of illumination, which causes a monotonic relationship between the source-detector
separation distance and the optically probed tissue depth. By carefully selecting the
source and detector separation distance, Raman scattered light collection can be op-
timized for a specific tissue depth [66]. More recently, Maher and Berger introduced
rigorous analytical formulation for optimizing the source-detector distance for the
purpose of maximizing the SNR of the desired tissue layer while minimizing that of
the interfering tissue layers [67]. This can be tremendously useful for optimizing the
Raman excitation and collection geometry for transdermal glucose detection, since
the skin, like many other biological tissues, have a layered structure (Fig. 4-1). The
outermost skin layer, the epidermis, does not have significant amount of glucose, as it
is mainly composed of the stratum corneum (dead skin cell barrier) and keratinocytes
which produce the stratum corneum. Beneath the epidermis are the dermis and the
subcutaneous tissue, where the cells are bathed in the interstitial fluid that contain
glucose. Therefore, for transdermal glucose detection, it would be beneficial to reject
the Raman scattered photons arising from the epidermis while accepting those from
the dermis and subcutaneous tissue.
Finally, for thin tissue samples, Raman spectra can be collected in transmission
mode. While SORS can be implemented even for thick tissues and offers the ability to
reduce the epidermal layer contribution in the collected Raman spectra, it requires a
ring-shaped collection geometry in order maximize the collection of Raman scattered
light from the same distance away from the illumination site. Since the Raman
scattered light needs to travel through the entire thickness of the tissue in order to
emerge from the other side, the transmission mode geometry may also provide a
similar reduction in the epidermal contribution while preserving or even enhancing
the dermal and subcutaneous tissue contribution. In order to test this hypothesis, a
Monte Carlo simulation was performed on a multi-layered skin model representing a
thin (1.5 to 5 mm) skin fold (such as the thenar skin fold). Beside elastic scattering,
the simulation also incorporated Raman scattering in order to provide a tissue depth
profile of Raman scattered photons for both transmission and back-scattered mode.
In addition, the tissue thickness, scattering coefficient and the Raman scattering
coefficient were varied to observe their effect on the tissue depth profile of Raman
scattered photons.
4.2 Estimation of transmitted and back-scattered
light power
Before studying the transmission mode Raman spectroscopy in detail, first a simple
ray tracing simulation was performed to see how much near infrared (NIR) light
power can be transmitted through the thin tissue (Fig. 4-2, Zemax Development
Corporation). Using typical skin optical parameters of p,=100 cm-1, pM=0.3 cm 1
and g=0.8 (at 830 nm), three tissue slabs of different thicknesses were each illuminated
from one side with a cylindrical beam of light (1 mm diameter). Light detectors were
placed both in the front and the back of the tissue in order to measure the power of
$As explained in Chapter 5, transmission mode geometry also offers enhancements in throughput
and Rayleigh rejection filter performance.
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Figure 4-2: Zemax simulations of light transmission and back-scattering in thin skin
tissues. Typical skin optical parameters of p,=100 cm-1, e,=0.3 cm-1 and g=0.8 (at
830 nm) were used. A 1 mm-diameter cylindrical beam of laser light (830 nm) was
illuminated from the right side of the tissue. A detector was place on the same side as
the site of illumination for back-scattered light measurement, while another detector
was placed on the other side of the tissue for transmitted power measurement. With
the incident light power at 100%, the measured powers are shown as percentages for
transmission and back-scattered modes.
near infrared light that was back-scattered from and transmitted through the tissue.
As the tissue thickness decreased from 3 mm to 2 mm and 1.5 mm, the transmitted
power increased from 7.4% to 21% and 34.2% of the incident light power, respectively
(Fig. 4-2). On the other hand, the back-scattered light power changed little at 9.9%
for 2 mm and 3 mm tissues, while it decreased to 9.5% for the 1.5 mm tissue. This
is because some of the light that would have returned back to the illuminated side
in the 2 mm and 3 mm tissues have been transmitted and failed to return in the
1.5 mm tissue. It should be noted that at 3 mm thickness, the transmitted power is
still comparable to the back-scattered power, and transmitted power actually exceeds
1.5 mm 3 mm
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Figure 4-3: Photon migration in skin tissue during a Raman scattering event.
back-scattered power for thicknesses less than 3 mm. (Another research group has
successfully performed transmission mode NIR Raman spectroscopy on a 16 mm
thick chicken breast tissue to detect calcifications embedded in the middle of the
tissue [68, 69].) However, these simulations do not incorporate Raman scattering
and therefore do not provide any information about where in the tissues the inelastic
scatterings occur. This information could be obtained by performing Monte Carlo
simulations described in the next section.
4.3 Monte Carlo simulation of Raman scattering
in thin multi-layered skin tissue
The thenar skin fold was chosen to be a candidate for performing transmission Raman
spectroscopy for glucose detection, due to its convenient location on the hand, thinness
of the tissue (2~4 mm), and relatively low level of pigmentation.5 The thenar skin
fold can be modeled as a multi-layered tissue structure (Fig. 4-3), which is composed
of a thin epidermis on the top and bottom layers, and the dermis/subcutaneous tissue
in the middle layer. The well-known multi-layered Monte Carlo simulation ANSI C
code developed by Wang et al. [71], was used as a starting point of the model. Since
this original code only included absorption and elastic scattering, it was modified to
implement Raman scattering. The basic steps of the overall procedure of the Monte
Carlo simulation were as follows:
1. Launch Raman excitation photon.
2. In a random manner, with probabilities according to the specified optical pa-
rameters, let the photon interact with the tissue by scattering and absorption.
3. For every tissue light scattering, randomly let the photon undergo a Raman
scattering with probability as specified by the Raman scattering coefficient.
4. Once a Raman scattering event occurs, record the physical location of the event
and continue to track the photon until it exits the tissue or gets absorbed by
the tissue.
5. Accumulate two separate records of Raman scattered photons, one for those
that were back-scattered toward the illumination source and the other for those
that were transmitted through the tissue at the opposite end.
Beside these basic steps, additional routines dealt with the treatment of photon
transport near the boundaries among the tissue layers and the air. A more detailed
representation of the Monte Carlo simulation procedure is shown in the flow chart of
Fig. 4-4. Here, s is the dimensionless step size to be taken by the photon for its next
§A previous NIR absorption spectroscopy study had suggested that the tongue would be a better
choice over the thenar fold for the noninvasive spectroscopic glucose measurement site [70]. This was
based on the fact that the fat tissue in the thenar fold could interfere with the NIR absorption spec-
troscopy measurement. However, NIR Raman spectroscopy offers superior chemical specificity than
NIR absorption spectroscopy, and the tongue tissue is less convenient for implementing transmission
geometry.
Figure 4-4: Flowchart for Monte Carlo simulation of photon transport and Raman
scattering in multi-layered skin tissue.
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random movement, which is determined by Beer's law [63]
P(s > si) = exp(-Itsi) (4.4)
where pt = Its + pa.
To accommodate uniform random sampling, the above equation can be repre-
sented in terms of a cumulative density function
S1  (5S = - = -ln (4.5)
pt
where ( was randomly sampled from 0 to 1 in a uniform manner. Similarly, the
propagation angle was randomly selected according to the specified anisotropy factor,
g, by using the Henyey-Greenstein phase function for bulk tissue scattering. Before
the photon hit a boundary delimiting the tissue layer, the distance to the boundary
db was calculated and subtracted from s so that the remaining step distance could be
used for crossing or bouncing away from the boundary.
During this random photon migration, the photon may undergo a Raman scat-
tering event. The probability of such event occurring depended on the value of the
Raman scattering coefficient relative to the Rayleigh scattering coefficient : goa
[72]. Once a Raman scattering event occurred, the boolean flag Flag v was set to
"TRUE" from the default value of "FALSE" in order to indicate that the photon had
undergone a Raman scattering event. At the same time, the location at which this
Raman scattering event had occurred was also recorded and the photon was tracked
until it met one of the three final fates :
1. Absorbed and "killed" by the tissue.
2. Exit the tissue by back-scattering.
3. Exit the tissue by transmission.
This procedure was repeated in a loop until the specified number of photons to be
launched were exhausted. The results of the simulation were two tissue depth profiles
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Figure 4-5: Tissue depth profile of the locations of Raman scattering for a typical
thenar skin fold of 3 mm thickness, with 0.1 mm-thick epidermal layers on the top
and the bottom. The Raman scattered photons collected in back-scattered mode
are shown in blue circles while those collected in transmission mode are shown in
red x's. (ps,epidermis=100 cm- 1, pRaman,epidermis=10-5 cm-1, Ila,epidermis:0.1 cm- 1,
gepidermis=0.8 , ps,dermis=100 cm-, pRaman,ermis=10-O cm- , pa,ermis=O.1 cm- 1,
gdermis=0.8.)
of Raman scattered photons, one collected in back-scattered mode and the other in
transmission mode.
4.4 Results and discussion
To simulate a typical human thenar skin fold of 3 mm thickness with 0.1 mm-thick
epidermal layers, the following default optical parameters were used:
ps,epiermis=100 cm-, paman,epidermis=1 cm-1, pa,epiermis=0.1 cm- , gepidermis=0.8 ,
ps,ermis=100 cm 1, [tRaman,dermis 10-5 cm-1, pa,dermisO.1 cm 1, gdermis= 0 .8.
Using these default values, Monte Carlo simulation was performed with 2 x 109
photons launched to the tissue illumination site, producing the tissue depth profile
of the locations of Raman scattering as shown in Fig. 4-5. In this figure, it can
be seen that the Raman scattered photons collected in back-scattered mode form
.. ..... ........ ...............
a very lopsided tissue depth profile, with stronger contributions from the shallower
depths. In contrast, the Raman scattered photons collected in transmission mode
form a relatively flat and even tissue depth profile, with the strongest contributions
coming from the middle of the tissue. This has important implications in transdermal
glucose detection, as the epidermal contains little glucose while most of the interstitial
fluid glucose is present in the dermal and subcutaneous layers. In the back-scattered
mode, having more Raman scattered photons coming from the epidermal layer may
cause stronger interfering Raman signatures that could be detrimental to glucose
detection. In the following parts of this discussion, simulations were repeated with
modified optical and tissue parameters to observe their effects on the tissue Raman
depth profiles.
4.4.1 Effect of tissue scattering coefficients
Figure 4-6 shows the effect of the tissue scattering coefficient on the tissue depth pro-
file of the Raman scattered photons. In this figure, the tissues with smaller scattering
coefficients had fewer Raman scattered photons, both in the back-scattered and trans-
mission modes. Despite the changes in the scattering coefficients, the general pattern
was unchanged: a lopsided back-scattered Raman tissue depth profile with heavier
contribution from the outermost layers, and a flat symmetric profile for transmitted
Raman photons.
4.4.2 Effect of tissue thickness
In the next set of simulations, the thickness of the skin fold was varied from 3 mm to
4 mm and 5 mm. As shown in Fig. 4-7, increasing the tissue thickness from 3 mm to
4 mm and 5 mm did not change the general qualitative characteristics of the back-
scattered and transmitted Raman photon tissue depth profiles. In order to study
the results in more detail, Table 4.1 was prepared to show the simulated values of
reflectance, transmittance and Raman scattered photons. In this table, the intensity
values are in terms of the fraction of the total light delivered to the tissue, which
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Figure 4-7: Skin tissue fold depth profile of Raman scattering for different tissue
thicknesses. With all other parameters kept constant, the tissue thickness was varied
from 3 mm to 4 mm and 5 mm.
Table 4.1: Reflectance, transmittance and Raman scattering
thicknesses (3 mm, 4 mm and 5 mm).
in tissues with different
Thickness Specular Diffuse Back-scattered Raman fraction
(mm) Reflectance Reflectance Raman of Reflectance
3 2.78 x 10-2 6.17 x 10-1 7.25 x 10-6 1.12 x 10-5
4 2.78 x 10-2 6.47 x 10-1 9.97 x 10-6 1.48 x 10-5
5 2.78 x 10-2 6.65 x 10-1 1.27 x 10-5 1.84 x 10- 5
has the value of 1. Therefore, the sum of specular reflectance, diffuse reflectance,
total transmittance, and the fraction absorbed by tissue is equal to 1. As expected,
varying the tissue thickness did not affect the intensity of specular reflection (Table
4.1). Also, as the tissue thickness increased, the total transmittance decreased while
the fraction absorbed by the tissue increased. Interestingly, however, the diffuse re-
flectance intensity also increased slightly as the tissue thickness increased, due to the
fact that less light is lost to transmittance for thicker tissues. As for the Raman scat-
tered photons, both back-scattered and transmitted Raman intensities increased as
the tissue thickness increase from 3 to 5 mm, due to the fact that the thicker tissues
allowed more opportunities for the photons to undergo Raman scattering. While the
back-scattered Raman intensities were similar to the corresponding transmitted Ra-
man intensities (Table 4.1), their relative fraction with respect to the total reflectance
and transmittance were different. In Table 4.1, the Raman fraction of reflectance was
calculated by dividing the back-scattered Raman intensity by the total reflectance
(specular + diffuse). Similarly, the Raman fraction of transmittance was calculated
by dividing the transmitted Raman intensity with the total transmittance. When
these values were compared, it can be seen that the Raman fraction of transmittance
was consistently higher than that of reflectance, and the difference between the two
were greater for thicker tissues. This is due to the fact that:
1. There is no contribution from specular reflectance in the transmitted photons
2. Traveling the entire thickness of the tissue increases the chances of undergoing
a Raman scattering event, while the photons collected in back-scattered mode
travel through a limited portion of the tissue as defined by the optical sampling
volume (hence the higher Raman fraction of transmittance for thicker tissues).
This could be beneficial for Raman spectroscopy instrumentation, since having a
greater fraction of Raman scattered photons could provide better rejection of Rayleigh
scattered light by the optical filters. However, needless to say, this trend cannot
continue indefinitely for much greater thicknesses, since, as the tissue thickness is
increased further to become semi-infinite, the back-scattered Raman intensity would
remain constant while the transmitted Raman intensity would diminish to zero due
to tissue absorption. In order to improve throughput for transmission mode Ra-
man spectroscopy, other researchers have suggested the use of a dielectric filter [73],
which forces the light reflected away from the tissue back towards the tissue, in the
direction of transmission. A similar concept was tested using a simple ray tracing
simulation by placing a reflector on the illuminated side of the tissue, which produced
5% improvement in transmitted Raman scattered light intensity.
4.4.3 Effect of Raman scattering coefficient
Finally, the Raman scattering coefficient y was varied to observe its effects on
the Raman tissue depth profile. In Fig. 4-8, pRaman was varied from 2 x 10, cm-
to 5 cm 1 while all other parameters (including p, = 100 cm- 1 ) were kept constant.
As expected, the number of Raman scattered photons increased with the Raman
scattering coefficient. For most values of paamn, the Raman tissue depth profile still
maintained the qualitative characteristics of having back-scattered Raman photons
heavily contributed by the outermost tissues, while the origins of transmitted Raman
photons had flatter and more even distribution throughout the tissue depth. However,
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Figure 4-8: Skin tissue fold depth profile of Raman scattering for different Raman
scattering coefficients. pRaman was varied from 2 x 10-5 cm- 1 to 5 cm-1 while all
other parameters (including p, = 100 cm- 1 ) were kept constant.
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this pattern started to break down at paaman values higher than 0.01 cm-- (Fig. 4-8).
Compared with p1, = 100 cm--1, these are unrealistically large values for paaman, since
spontaneous Raman scattering event typically occurs once every 106 ~107 elastic
scattering events. (However, the simulation results for these large paaman values may
be useful for studying other spectroscopic modalities such as fluorescence, which may
have much higher probability of excitation than spontaneous Raman scattering.)
4.5 Conclusion
In this chapter, Monte Carlo simulations were employed to study the distribution of
Raman scattering events along the depth of a thin skin tissue fold, for both back-
scattered mode and transmission mode Raman spectroscopy. The study has shown
that Raman scattered photons collected in back-scattered mode have higher contri-
butions from shallower tissue depths, while those collected in transmission mode have
a more even and symmetric distribution of contribution along the entire depth of the
tissue. This could be beneficial for transdermal glucose detection, since the contri-
bution from the interfering epidermal layer can be reduced. In addition, it has been
shown that for the skin tissue fold, the fraction of Raman scattered light is higher
in transmission mode than that in back-scattered mode. This could help reduce the
amount of Rayleigh scattered light that needs to be removed by the optical filters.
In conclusion, collecting Raman spectra in transmission mode for transdermal glu-
cose measurement is not only feasible, but also accompanies several advantages over
conventional back-scattered mode collection.
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Chapter 5
Development of clinical Raman
spectroscopy instrument
5.1 Introduction
With the exception of a few transparent tissues such as the ocular lens, most bulk
biological tissues are highly scattering even in the near infrared (NIR) regime. On the
other hand, many optical systems can receive light only at a limited range of angles
specified by their effective numerical apertures. This is particularly problematic for
designing a suitable Raman spectroscopy-based diagnostic device, as efficient light
collection is crucial due to the inherently weak nature of Raman scattered light. For
this reason, Raman spectroscopy instruments used for the analysis of bulk biological
tissues often require a light collection device that redirects the light scattered at steep
angles to be collimated within a limited range of conic half angles with respect to
the receiving optical system. This had been previously achieved by the use of a half
paraboloidal mirror [57], plano-convex lens [74], sapphire ball lens [75, 76], and a com-
pound parabolic concentrator (CPC) [77, 76]. However, many of these strategies have
certain shortcomings. For example, while Raman scattered photons can back-scatter
in all directions when the excitation light impinges on the tissue surface (due to the
sequence of multiple scattering events in the tissue), the half paraboloidal mirror
surrounds only a portion of the illuminated tissue surface and fails to collimate the
Figure 5-1: Compound parabolic concentrator (CPC) coupled to an optical fiber
bundle for enhanced Raman light collection.
light being scattered away from the mirror. The plano-convex collimation lens has a
limited acceptance angle defined by its numerical aperture. Finally, the sapphire ball
lens itself could create significant Raman signals and confound the intrinsic tissue
Raman spectra.
All of these issues mentioned above can be resolved by using a hollow gold-coated
CPC. A CPC completely surrounds the illuminated tissue site (3600) to efficiently
collect Raman scattered light at all conic half angles (-900 to 90'). In addition,
the gold-coated surface efficiently reflects the NIR Raman scattered light without
generating Raman signatures of its own. This chapter describes a portable clinical
Raman spectroscopy instrument that has been designed to incorporate a CPC-based
optical fiber probe. The CPC was designed using ray-tracing simulations and man-
ufactured using computer-controlled machining and electroforming techniques. The
performance of the CPC was tested to show a significant enhancement in Raman
scattered light collection.
5.2 The compound parabolic concentrator
However, the utility of CPC is limited when a very high degree of light collimation is
desired, as its physical dimensions become impractically large for manufacturing or
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Figure 5-2: Compound parabolic concentrator (CPC).
use. In order to circumvent this problem, the portable clinical Raman spectroscopy
instrument was also designed to incorporate a non-imaging optical element called
compound hyperbolic concentrator (CHC). Unlike the CPC, the CHC coupled with a
matching lens allows the instrument to efficiently collect Raman spectra from highly
scattering biological tissues by collimating the Raman scattered light within a very
narrow range of half angles, while also maintaining much smaller physical dimensions
than a CPC.
5.3 The compound parabolic concentrator
The compound parabolic concentrator (CPC) is a non-imaging optical element formed
by the revolution of two tilted and offset parabolae (Fig. 5-2). It has two apertures:
a minor aperture defined by the two parabolic foci, and a major aperture at the other
end. The smaller aperture can accept light rays at all angles (half angles -90' to 900),
while the larger aperture can only accept light rays entering at a limited range of
angles, as defined by the angle between the parabolic axes (Fig. 5-2). Depending
on its application, either CPC aperture can serve as the light input while the other
aperture is used as the output. Originally, the CPC was designed to accept sun rays
from the major aperture while concentrating the light through the minor aperture
for efficient solar energy collection [78]. Conversely, such as in light emitting diode
illuminators [79], the minor aperture can be used as the input to collect light scattered
at all angles (half angles -90* to 900), while collimating the light at the output (major)
aperture to be within a limited range of angles. It should be noted, however, that
when used as a collimator, the CPC does not conserve the 6tendue. In order to
conserve the 6tendue, the two apertures must satisfy the following
S1A 1 = S2Q 2  (5.1)
where S denotes the aperture area and Q is the solid angle. For circular areas and
conic angles (Q = 2r (1 - cos 0)=4r sin 2 (2)), this becomes
4wr sin 2  = 47r sin 2  ) (5.2)
which simplifies to
r2 _ sin (01/2) (5.3)
ri sin (02/2)
Since a CPC accepts 27 solid angle at the minor aperture, the etendue matching
equation becomes
rMajor. 
- ___ 
_ 0-707 54
rminor sin (0m,;/2) sin (0ma/2)
where Om,, is the maximum half angle of collimation. However, for a CPC, the
etendue at the major aperture is smaller than that of the minor aperture, due to the
following relationship of the CPC apertures
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rminor sin Oma sin (0maz/2)
- Major / r minor: Etendue Conservation
600 
____ rMajor minor
500
0
400
0
ii 300-
200-
100-
0 2 4 6 8 degrees 14 16 18 20
0max dges
Figure 5-3: rMajor for Stendue conservation and CPC.
rminor
This can be visualized in Fig. 5-3 and Fig. 5-4, which suggest that the 6tendue
is conserved when the rays enter from the major aperture, while it is not conserved
when the rays enter from the minor aperture.
Despite these limitations when used as a collimator, the CPC can still provide a
significant enhancement in the collection of Raman light scattered from turbid tissues,
by accommodating the limited numerical aperture of the collecting optical system
[77]. This is illustrated in Fig. 5-5, which shows the results of ray-tracing simulations
(Zemax Development Corporation) comparing different types of reflectors. In each
simulation, an isotropically scattering light source (0.8 mm diameter, matched to the
size of the reflector aperture) is placed on the left of the reflector while a detector with
a limited range of acceptance angles (12.70 or less) is placed on the right. Without
any reflector, only 6% of the light was detected, while 74% of the light was detected
with a conical reflector. With a paraboloidal reflector, which appears to be similar to
CPC, still collected only 75%. However, with a CPC, 97% of the light was detected,
demonstrating that the CPC performance cannot be matched by a similarly shaped
paraboloid.
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Figure 5-4: Ratio of quantities described in Fig. 5-3.
5.3.1 Designing the CPC
As shown in Fig. 5-2, the main CPC design parameters include the minor aper-
ture radius rminor, the major aperture radius rMajor, and the maximum half angle
of collimation 0 max. From these parameters, the overall dimensions of the CPC are
determined. The focal length, f, of the parabolae is defined as [80, 81]:
rminor
1 + sin Omax (5.6)
and the overall CPC length, L, is defined as:
L rminor (1 + sin Omax)
tan Omax sin 0max
(5.7)
Finally, the major and minor aperture radii are related as follows:
rMajor 
-
rminor
sin 0max
0.9'
O0
(5.8)
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Figure 5-5: Comparison of collection performance in different reflectors.
When designing the CPC for tissue Raman spectroscopy, the major aperture radius
rMajw. is typically constrained by the requirements of the receiving optical system. For
example, if the CPC is used for enhancing light collection by an optical fiber bundle
coupled to a spectrograph and a CCD detector, rMaj, is limited by the maximum
slit height permitted by the spectrograph-CCD system. With this constraint, the
remaining two parameters, rminox and m, can be optimized.
When the Raman excitation light impinges on a single point on the turbid tissue
surface (e.g. skin), it undergoes diffuse scattering and spreads throughout the tissue
volume. Therefore, in order to maximize throughput, Raman scattered light should
be collected from an area much larger than the illuminated spot on the tissue surface.
Since the CPC cannot collect the light beyond the limits of its input aperture, a
greater input aperture size is desirable to permit as many photons as possible. How-
ever, in order to increase rmino, the maximum angle of collimation 0m, would also
have to be increased, which cannot be done indefinitely as the optical system has a
limited numerical aperture. Although Om,, could be set equal to the system numeri-
cal aperture, it may not be optimal as a larger rmine at the expense of Oma2 greater
than the system numerical aperture could provide an overall gain in throughput. To
arrive at the optimal trade-off, a ray-tracing ZEMAX simulation was performed at
various combinations of rmin, and Om,. In Fig. 5-6, it can be seen that as rminx was
increased beyond the value obtained by setting 6ma, equal to the system numerical
aperture (rminow=0. 4 mm), the collected light power also increased until it reached a
maximum, beyond which Oma, became too much greater than the limit of the system
numerical aperture and the collected light power started to decrease.
5.4 The compound hyperbolic concentrator
5.4.1 Advantage of CHC over CPC
As mentioned previously, the CPC can be used as a collimator by using its minor
aperture as input. Tanaka et al. proposed the use of a hollow gold-coated CPC as a
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Figure 5-6: Optimization of CPC input aperture radius. Using Zemax ray-tracing
simulations, the power of light collected within ±90' and ±12.70 were monitored
while the input aperture radius rminor was increased from 0.4 mm to 0.9 mm. At the
same time, Omax was also varied accordingly to maintain a constant output aperture
radius of rMao, = 1.8 mm.
collimator to facilitate Raman scattered light collection from biological tissues by an
optical fiber probe with a limited numerical aperture (0.29 NA), and demonstrated
seven-fold enhancement in collection efficiency compared with the same optical fiber
probe without the CPC [77]. However, many bulk tissue Raman spectroscopy systems
call for an even higher degree of collimation than required by the numerical aperture
of the collection optical fibers and spectrographs, as certain dielectric and holographic
optical filters are effective only at a very limited range of incident angles. For example,
both the optical density as well as the band center of the holographic notch filter
varies significantly with the angle of the incident beam [82, 83]. While this property
is very useful when filtering collimated beams, as it allows fine adjustment of the
stopband wavelengths by angle tuning [82, 83], it could significantly reduce the filter
performance when collecting photons that are multiply-scattered in a wide range of
angles. This has important implications in bulk biological tissue Raman spectroscopy
as most bulk tissue samples are highly scattering and Rayleigh scattered light needs to
be filtered out efficiently in order to obtain a Raman spectrum of acceptable quality.
Although a CPC can be designed to achieve a very high degree of collimation
to facilitate good filter performance, it would require very large physical dimensions
relative to a given input aperture size. For a given input aperture rmno. and the
maximum collimation half angle 0m,, the length of the CPC, L, is defined by eq.
5.7. When this equation is plotted, as shown in Fig. 5-7, the length of the CPC rapidly
becomes very long and approaches infinity as the desired maximum collimation half
angle gets closer to zero degrees. However, the required length of the nonimaging
optical element can be significantly reduced by introducing the CHC (Fig. 5-8).
Unlike the CPC, whose reflector surface is defined by rotating the curve formed
by two tilted and offset parabolae [77], the CHC is defined as a surface of revolution
whose cross sectional profile is defined by two hyperbolae that are mirror images about
the horizontal axis (Fig. 5-9(A)) [81]. In addition to the reflector itself, the CHC
also requires a matching focusing lens with the focal length defined by the distance
between the output aperture and the focus on the opposite side of the symmetric
axis of the hyperbola (Fig. 5-9(A)). This combination effectively allows the CHC to
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Figure 5-7: CPC lengths with respect to maximum collimation conic half angles for
input aperture radius of 2 mm. Maximum half angle of zero degrees corresponds to
perfect collimation.
function as a CPC with much larger dimensions (Fig. 5-8(B)). In Fig. 5-8(A), both
the CPC and the CHC have an input aperture diameter of 4 mm, and are capable
of converting the input light directions from half angles as wide as ±900 to ±3.9' or
less. However, the CPC length is 460 mm while the CHC length is only 115 mm. The
CHC can achieve the same effect as a very long CPC while also maintaining much
smaller physical dimensions by using a lens that has its focus point at the opposite
hyperbolic focus (Fig. 5-9(A)). As shown in Fig. 5-8(B), due to the hyperbolic shape
of the reflector, the light is redirected in a manner such that light emanating from
point I at the input aperture of the CHC acts as if it were coming from point II,
which lies on the lens' focal plane.
5.4.2 Designing the CHC
The input aperture radius Ri of the CHC was defined by the distance between the
horizontal axis and the focus fiB (or fiA) of the hyperbola (Fig. 5-9). As mentioned
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Figure 5-8: (A) Comparison of CPC and CHC with the same input aperture size
and degree of collimation. Both CPC and CHC have input aperture radius of 2 mm
and maximum collimation half angle of 3.90. (B) The CHC functions as a CPC of
much greater length with the help of a matching focusing lens. Due to the hyperbolic
shape of the reflector, light emanating from point I (the actual focus of the lens) are
collimated by the lens as if it were coming from point II.
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Figure 5-9: (A) CHC formed by two hyperbolae and its associated design parame-
ters. Rj: input aperture radius, R,: output aperture radius, L: CHC length, Omax:
maximum collimation conic half angle, 4: angle between the two hyperbolae, fiA,
f2A, fiB, f2B: foci of hyperbolae. The diameter and focal length of the matching
plano-convex focusing lens are clearly defined by R, and the distance between the
output aperture and the hyperbolic foci (f2A and f2B). (B) CHC design optimized
for the clinical Raman instrument.
previously, for transdermal glucose detection, it is desirable to have a large input
aperture radius in order to accept as many Raman scattered photons as possible
(unlike imaging applications that require high spatial resolution). The major (output)
aperture radius R, was defined by the distance between the horizontal axis and the
intersection of the hyperbola and the line connecting the foci fiA and f2B (or, fiB
and f2A). This dimension was constrained by the largest available lens with a focal
length equal to the distance between the output aperture and the line connecting
the foci f2A and f2B. Finally, the maximum half angle 0m, of collimated light was
defined by the angle between the horizontal axis and the line connecting the center
of the output aperture to the focus f2A (or f2B). Since the CHC was to be placed
in front of a holographic notch filter designed to accept a collimated beam, 0 m. was
minimized for optimization.
With these constraints, the adjustable parameters included the angle # between
the transverse axes of the two hyperbolae (Fig. 5-9), and the shape of the hyperbolae
as defined by A and B of the hyperbolic equation:
X2  
- 1 (5.9)
A2 B 2
The final result of the optimization was a CHC with 2 mm input radius, 26 mm
output radius, length of 115 mm, and 0,. of 3.9* (Fig. 5-9(B)).
5.5 Manufacturing the CPC and CHC
Identical procedures were used for manufacturing the CPC and the CHC. The opti-
mized design was first verified for performance by using ray-tracing simulations (Fig.
5-10, ZEMAX Development Corporation) and transferred to a computer-aided man-
ufacturing program (Mastercam, CNC Software, Inc.). Using a computer numerical
control (CNC) lathe machine (HAAS Automation, Inc.), an aluminum mandrel of
the CHC was manufactured to high accuracy (error less than 5 pm) and polished to
optical grade fineness (0.1 pm) (Fig. 5-11).
The mandrel was then deposited with a layer of nickel by using a nickel sulfamate
Detector f/2 5.2 cm
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Figure 5-10: ZEMAX ray-tracing simulation for design verification. The optimized
CHC design of Fig. 5-9B was imported into ZEMAX, and coupled with a matching
plano-convex focusing lens of 150 mm focal length. Another focusing lens of f/2 was
placed in front of the CHC output aperture, and a detector was placed near its focus.
In order to simulate the limited numerical aperture (f/2) of the collection fiber bundle
(Fig. 5-13), the detector only accepted light coming in at conic half angles of ±14 or
less. With an isotropic light source (conic half angle ±90' or less) at the CHC input
aperture, the detector received 78% of the original light intensity.
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Figure 5-11: Manufacturing the CPC and CHC.
electroforming process (Caswell, Inc.). The mandrel was then released by dissolving
the aluminum in a warm (40 C) sodium hydroxide solution while leaving the nickel
intact to create the hollow nickel CPC and CHC shells. After an electroless bright
nickel electroplating process [84] for enhanced reflectivity and secondary polishing to
optical grade fineness (0.1 pm), the CPC and CHC were electroplated with a uniform
layer of pure gold (99.9%) in order to improve NIR reflectivity (>98% at 830 nm)
(Figs. 5-11).
Figure 5-12 describes a test for the performance of the manufactured CPC. An
830 nm laser light was illuminated on the quartz cuvette holding a powder sample
of acetaminophen. On the other side of the sample, a CPC-equipped optical fiber
probe was placed to collect the Raman spectrum. Then another Raman spectrum
was collected with the same optical fiber probe and aperture, but without the CPC.
Tanaka et al. derived the CPC enhancement factor (p) by forming the radiance
intensity ratios [77]:
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Figure 5-12: Testing the performance of CPC. Top: An 830 nm laser light was
illuminated from the top, onto the quartz cuvette holding a powder sample of ac-
etaminophen ("Tylenol"). On the other side of cuvette, a CPC-based optical fiber
probe was placed to collect the Raman spectrum of the sample. Bottom: Raman
spectra collected by the optical fiber probe with the CPC (red) and without the CPC
through an equally sized aperture (blue).
where numerator describes the radiance at the minor aperture and the denominator
describes that of the major aperture. For highly turbid media such as biological
tissues, the Raman scattered light distribution is Lambertian, with L (0, <) = L" cos 0.
This makes the enhancement factor to be
2 2
p = - 20.7 (5.11)(1 - cos 20,m.) (1 - cos 25.40)
However, this formulation ignores the 6tendue conservation. As shown in section 5.3,
the 6tendue of the CPC is not conserved when the minor aperture is used as input
(although this effect is pronounced only at very small maximum half angles (0m.2)).
By incorporating the 6tendue factor of eq. 5.5, the enhancement ratio then becomes
2 sin (0m,/2) 2 sin (6.35")
= (1 - cos 20ma) 0.707 sin (m 2) (1 - cos 25.40) 0.707 sin (12.70) = 14.7 (5.12)
As shown in Fig. 5-12, the CPC enhanced the Raman spectral peak intensities by
about four times, in contrast to the theoretically possible enhancement of 14.7 times.
This may be due to two possible reasons:
1. Shape deviation due to errors in machining.
2. Imperfections in mirror polishing (0.1 pm).
Ray-tracing simulations performed by Tanaka et al. showed less than 20% reduction
in throughput for 1% shape deviation [771. As the CNC lathe machine has a very
high accuracy (error less than 5 pm) relative to the dimensions of the CPC and CHC
(errors are in the range of 0.1 to 0.01%), the major contributor to the performance
degradation may be the reduced reflectivity due to imperfections in mirror polishing.
To analyze the effect of surface roughness on reflectivity, the Rayleigh criterion can
be expressed as
47rh cos (5.13)A
where h is the height of the imperfections on the mirror surface -Y is the incident
angle of the light beam and A is the light wavelength. Since A# = 7r gives destructive
interference, an approximate condition for optical gloss can be set as
AO> < -(5.14)2
which translates to
h < (5.15)
8 cos
At 830 nm, this sets the upper limit of h to 0.1 pLm, which is barely matched by
the grit size used in the mirror polishing. Therefore, further improvements in the
throughput could be achieved by employing better polishing techniques with even
smaller grit size lapping compounds.
5.6 The clinical Raman spectroscopy system
The clinical Raman instrument was designed to collect Raman and diffuse reflectance
(DRS) spectra in transmission mode from thin tissues (Fig. 5-13). It used an 830
nm diode laser (Process Instruments) for Raman excitation, and a broadband source
(AvaLight-HAL-S, Avantes) for DRS measurements (DRS provides useful information
for tissue turbidity correction in tissue Raman spectroscopy [35, 34, 33]). These
sources were delivered to the tissue via separate optical fibers (400 pLm core, 440Lm
cladding, 0.26 NA, Fiberguide Industries). In particular, the Raman excitation fiber
had a shortpass fused silica filter rod (0.62 mm diameter, Barr Associates) at the distal
tip, in order to suppress the Raman scattered photons generated by the excitation
fiber itself.
After the Raman excitation light was scattered and transmitted through a thin
tissue (e.g., the thenar fold of an adult human hand, ~3 mm thick), the Raman
scattered light was collected from the opposite side of the tissue by the CHC (Fig.
5-13). The CHC, coupled with a 50 mm diameter focusing lens of focal length 150
mm, redirected any scattered photons (half angles within ±900) transmitted through
its input aperture to be within a narrow range of angles (half angles within ±3.90),
collimating the scattered light to 0.068 NA. The collimated light was then filtered
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Figure 5-13: Transmission mode clinical Raman spectroscopy setup with CHC. (NDF:
Neutral density filter, BPF: Bandpass filter, S: Shutter, FL : Focusing Lens, OFB:
Optical fiber bundle.) With the Raman excitation light illuminated on one side of the
thin tissue sample (such as the thenar skin fold), the Raman scattered light emerges
from the other end of the tissue. The CHC collects Raman scattered light at all
conic half angles (±900) and collimates to within ±3.90. The collimated light is then
filtered through a holographic Rayleigh rejection notch filter and focused onto the
collection fiber bundle. On the other end, the collection fiber bundle is arranged to
form a column of light with its height matched to the size of the CCD detector.
through a 50 mm diameter 830 nm holographic notch filter (Kaiser Optical Systems,
Inc.), which efficiently rejected the Rayleigh scattered light while transmitting Raman
scattered light. Without collimation by the CHC, the light would have reached the
filter at a wide range of angles and the filter performance would have been degraded
as its stopband wavelength and optical density varied with the angle of the incident
light [82, 831. The filtered light was then focused onto an optical fiber bundle (1.5
mm diameter, Romack, Inc.) composed of 37 closely packed (76% packing fraction)
jacket-stripped collection fibers (200 pm silica core, 220 Am silica cladding, 0.26 NA,
Fiberguide Industries) (Figs. 5-13, 5-14). The proximal end of the transmission mode
collection fiber bundle (facing the spectrograph input) formed a single 8 mm column
of optical fibers to match the height of the CCD detector. The fiber bundle length
was limited to 50 cm in order to minimize the generation of undesirable background
Raman spectra from the collection fibers, arising from any stray Rayleigh scattered
photons that might have leaked through the notch filer. The collected Raman scat-
tered light was then dispersed by the spectrograph (f/2, 6.23 nm/mm dispersion, 4.8
cm-1 spectral resolution, LS 785, Princeton Instruments) and detected by a back-
illuminated deep-depletion CCD with 1340x400 array of pixels (each pixel 20x20
im), thermoelectrically cooled to -70*C (Spec-10:400BR, 75% quantum efficiency at
850-960 nm), Princeton Instruments). The entire setup fitted inside a wheeled cart
(37x18x42 in.) to facilitate portability during its use in the clinical setting.
For convenient access to remote and obscure areas of the human body, the in-
strument could also use an optical fiber probe (3.5 mm diameter) to collect Raman
spectra in back-scattered mode (Fig. 5-15). The optical fiber probe was composed
of a CPC, a Raman excitation fiber, a DRS excitation fiber, 17 collection fibers (400
ptm core, 440pm cladding, 0.26 NA, Fiberguide Industries), a custom manufactured
fused silica notch filter tube (0.97 mm inner diameter, 3.47 mm outer diameter, Barr
Associates) and a shortpass filter rod (0.62 mm diameter, Barr Associates)[75, 85]
(Fig. 5-15). Although a CPC of length 9 mm was sufficient for accommodating
the 0.26 NA of the optical fibers, a CHC of a similar size coupled with a matching
focusing lens would provide a much higher degree of collimation required for better
Figure 5-14: CHC-based clinical Raman spectroscopy instrument used for human
subject studies. (A) The entire instrument fits inside a wheeled cart to facilitate
portability during clinical studies. (B) The manufactured CHC seen from the output
aperture. The interior surface was evenly coated with pure gold and polished to
optical grade fineness. (C) Side view of the transmission mode Raman spectroscopy
setup.
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Table 5.1: Comparison of system throughputs of bench-top system and the portable
clinical system in back-scattered mode (CPC-based) and transmission mode (CHC-
based).
Throughput Bench-top[87] Portable, CPC Portable, CHC
Factors (Back-scattered) (Back-scattered) (Transmission)
Collection efficiency 21% 41% 59%
Packing fraction 62% 25% 76%
AR coatings 64% 90% 90%
CCD detector 60% 75% 75%
Total 5% 7% 30%
notch filter performance. In addition, depending on the requirements for the specific
tissue targets, other back-scattered mode probe configurations such as oblique angle
illumination [74, 86] and dichroic mirrors [77] could be employed.
5.7 System performance
5.7.1 Throughput
In Table 5.1, the throughput and efficiency of a bench-top Raman spectroscopy system
[87] was compared with those of the portable system in the two available modes.
The bench-top system operated in back-scattered mode, with a half paraboloidal
mirror as the primary collecting optic, and an optical fiber bundle for coupling the
collection optics with the spectrograph. The portable system could be operated in
back-scattered mode with a compact CPC-based optical fiber probe. The collection
efficiency of the CPC (41%) was much higher than that of the half paraboloidal mirror
(21%) used in the bench-top system. However, the optical fiber packing fraction
was much lower in the portable system (25%, as opposed to 62% of the bench-top
system). This was due to the complexity in the compact optical fiber probe design,
which sacrificed much of the collection area to the central excitation fiber and custom
manufactured optical filters (Fig. 5-15). On the other hand, the portable system
used more recent AR coating and CCD technologies, which provided a slight increase
in throughput (Table 5.1). The overall throughputs of the two systems were very
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Figure 5-15: Back-scattered mode Raman spectroscopy system with a CPC-based
optical fiber probe. Although the CPC of length 9 mm was sufficient for accom-
modating the 0.26 NA of the optical fibers, a CHC of a similar size coupled with a
matching focusing lens would provide a much higher degree of collimation required for
better notch filter performance. (NDF: Neutral density filter, BPF: Bandpass filter,
S: Shutter, FL : Focusing Lens, OF: Optical fiber, OFB: Optical fiber bundle.)
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Figure 5-16: Estimation of minimum detectable glucose concentration. SNR of the
Raman spectra collected from aqueous glucose solutions at concentrations of 125 mM,
500 mM and 1 M. Extrapolation to SNR=1 gave 0.39 mM, which corresponded to
the minimum detectable glucose concentration of 1.2 mM (or 22 mg/dl).
similar: 5% for the bench-top system and 7% for the portable CPC-based system.
The throughput of the portable clinical Raman spectroscopy system increased
significantly when converted into CHC-based transmission mode. Both the collection
efficiency (59%) and the optical fiber packing fraction (76%) were superior to the
bench-top system, with an overall throughput of 30% (Table 5.1). Even when the
AR coating and CCD efficiency values were matched with the bench-top system, the
overall throughput was 17%, which is still significantly higher than the 5% throughput
of the bench-top system.
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5.7.2 Minimum detectable glucose concentration
In order to estimate the minimum detectable glucose concentration, Raman spectra
were collected from aqueous glucose solutions of concentrations 125 mM, 500 mM and
1 M. Although normal physiological glucose concentrations rarely rise above 20 mM,
these concentrations were used to facilitate accurate estimation of the signal-to-noise
ratio of the spectra. At each concentration, the SNR of the collected Raman spectra
were plotted against the corresponding concentrations (Fig. 5-16). By extrapolating
these points with a line towards lower SNR values, and the glucose concentration
corresponding to SNR=1 was noted to be 0.39 mM. This is estimated to the noise
equivalent glucose concentration, as define previously by eq. 3.10. The minimum
detectable glucose concentration can then be estimated by multiplying this value
with the spectral overlap (non-orthogonality) factor, which was roughly estimated to
be 3 [56]. Hence, the minimum detectable glucose concentration of the clinical Raman
spectroscopy system was estimated to be 1.2 mM or, equivalently, 22 mg/dl.
5.7.3 Clinical data collection
Many biomedical Raman spectroscopy applications such as cancer [88, 89, 90] and
atherosclerosis detection [91, 92, 93] look for changes in the bulk tissue composition
and morphology reflecting the pathology, which are well represented in the tissue
Raman spectra. However, in the application of Raman spectroscopy for transdermal
glucose level measurement, Raman signatures of aqueous glucose contribute only a
very small fraction of the total tissue Raman spectra [94, 25]. As such, the perfor-
mance of non-invasive glucose detection depends even more heavily on the quality of
the Raman spectrum.
As described in Chapter 6, the CHC-based clinical Raman instrument was used
successfully in a study that aimed to determine the clinical feasibility of using Raman
spectroscopy for non-invasive glucose measurement. In that study, Raman spectra
were collected from the thenar skin fold of the hands of human volunteers in transmis-
sion mode during oral glucose tolerance tests (OGTT), where the subjects ingested
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a glucose-rich beverage to induce changes in blood glucose levels. At the same time,
reference blood glucose levels were measured by using conventional finger-prick glu-
cometers (SureStep Flexx, Johnson and Johnson). This protocol produced a set
of skin Raman spectra (each composed of 1340 CCD intensity values) with corre-
sponding reference blood glucose values. A calibration algorithm relating the Raman
spectra to the corresponding glucose concentrations can be developed by using var-
ious chemometric techniques [50], such as partial least squares [95, 96], principal
component regression [96] and support vector regression [97, 58, 39]. Support vector
regression was performed on the data obtained with the clinical Raman instrument
to create a calibration model for non-invasive glucose detection. Performing leave-
one-out cross-validation of this model on the dataset showed good correlation between
the concentrations predicted by Raman spectroscopy and the conventional finger-stick
glucometer readings. This was achieved while using an 8 mm-height CCD detector
with 1340x400 array of pixels (Princeton Instruments), 100 mW Raman excitation
laser power and 1 minute acquisition time for each data point. Previous OGTT stud-
ies using a laboratory-based back-scattered mode instrument including a paraboloidal
mirror and a 25.4 mm-height CCD detector with 1340x 1300 array of pixels (Roper
Scientific) required 200~300 mW Raman excitation laser power and 3 minute ac-
quisition time for each data point, in order to achieve similar level of performance
[57, 34].
5.8 Conclusion
A portable clinical Raman instrument has been developed using a CHC and a match-
ing focusing lens. The CHC and lens combination achieved a very high degree of
collimation for enhanced tissue Raman scattered light collection and efficient notch
filter performance, while maintaining much smaller physical dimensions than a CPC
designed to achieve the same. The instrument has been used successfully for collecting
skin Raman spectra from human volunteers during OGTT, while using lower Raman
excitation laser power and shorter acquisition times compared with laboratory-based
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systems with similar performance. Besides collection of Raman spectra from skin tis-
sues, the proposed CHC design could have many other uses in spectroscopy systems
requiring efficient collimation of nearly isotropically scattered light from biological
tissues.
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Chapter 6
Human clinical study
6.1 Introduction
While artificial tissue phantoms can be studied in the laboratory settings to provide
an insight into the clinical feasibility of Raman spectroscopy for transdermal glucose
detection, these studies cannot completely replicate the real-life clinical conditions.
Similarly, animal models, while tremendously useful, have limitations due to differ-
ences in the skin physiology and glucose metabolism compared with those of humans.
Therefore, collecting and analyzing the skin Raman spectra from human subjects
provide a unique opportunity to gain direct insight into the requirements for clini-
cal translation of Raman spectroscopy for glucose measurement. In this study, the
portable clinical Raman spectroscopy instrument described in Chapter 5 was used at
the MIT Clinical Research Center (MIT CRC, Co-directors: John Gabrieli, Ph.D. and
Ravi Thadhani, M.D., M.P.H.) to collect skin Raman spectra from human subjects
undergoing an oral glucose tolerance test (OGTT). The measured Raman spectra
and reference blood glucose concentration values were used to develop a calibration
model, which was then tested for accuracy.
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Figure 6-1: Glucose analyzers used for reference blood glucose measurements. Left:
Siemens, Dimension Xpand, Right: Johnson and Johnson, Life Scan, SureStep Flexx.
6.2 Materials and methods
6.2.1 Reference blood glucose measurements
The accuracy of glucose concentration estimated by Raman spectroscopy and its
calibration model cannot exceed the accuracy of the reference blood glucose measure-
ments. For this reason, it is crucial to have a very accurate method of measuring
glucose concentration to serve as the "gold standard" reference. The MIT CRC
is equipped with a set of two clinical blood glucose meters (Johnson and Johnson,
Life Scan, SureStep Flexx) (Fig. 6-1, right). Every month, these glucometers are
calibrated against a more sophisticated and accurate chemical analyzer (Siemens,
Dimension Xpand) (Fig. 6-1, left) by the MIT Medical Laboratory Department, to
maintain an average precision of 3 to 4 mg/dl. Figure 6-2 shows typical calibra-
tion curves for both MIT CRC meters generated by the MIT Medical Laboratory
Department, which both have an R2 value of 0.99 or higher.
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Figure 6-2: Calibration results for MIT CRC SureStep Flexx glucometers.
6.2.2 Arrangement of instruments and the human subject
The portable clinical instrument described in Chapter 5 was placed next to a hospital
bed (Fig. 6-3), while the glucometers, lancets and other clinical supplies were placed
on the other side of the bed. This was to facilitate simultaneous recording of skin
Raman spectra and blood glucose concentrations from either side of the bed while the
human subject sat on the bed. More importantly, for the safety of the human subjects,
it is essential to perform the study with the subject resting on a bed, as frequent finger-
pricks could trigger a vasovagal syncope in at least 10% of U.S. population due to
needle phobia [3]. Vasovagal syncope is a nerve reflex response due to noxious stimuli
(such as needle sticks) which induces fainting in the individual by sudden drop in
blood pressure and reduced blood perfusion in the brain. When this happens, it is
essential that the patient be placed in a "Trendelenburg position" (which is a supine
position with the patient's legs raised above the head level [98]) in order to promote
blood perfusion to the brain and help the patient return to consciousness. Although
this is normally not a life-threatening event, there are documented cases of seizure and
fatality due to vasovagal syncope [3, 99]. Such adverse effects of invasive blood glucose
monitoring methods further motivate the need for a non-invasive glucose monitoring
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SureStepFlexx CRC-1 vs. Xpand
Figure 6-3: The clinical Raman spectroscopy instrument located next to a hospital
bed at the MIT CRC. After 8 to 12 hours of fasting, the human subject (shown here
as a mannequin to protect confidentiality) sits on the hospital bed and drinks the 75 g
glucose beverage (top right). For the next 2 to 3 hours, Raman spectra were collected
from the subject's right hand using the clinical Raman instrument while conventional
finger-stick blood glucose measurements were made simultaneously from the left hand.
device. In order to minimize the possibility of vasovagal syncope, human subjects
were screened before the study based on prior history of needle phobia or fainting.
Despite these precautions, three vasovagal episodes occurred during this study with
no adverse consequences to the human subjects.
6.2.3 Data acquisition and OGTT protocol
Prior to the beginning of the study, the human subject was required to fast for at
least 8 to 12 hours, to ensure that the study was started at the fasting glucose level.
If the fasting glucose level was above 125 mg/dl, the study was interrupted and
the subject was discharged (as this indicates abnormality in the subject's glucose
regulation ability and it may also prevent the collection of spectral and blood glucose
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Figure 6-4: Thenar skin fold Raman spectra collected from one human subject during
OGTT. Left: Raw, unprocessed Raman spectra. Right: Raman spectra processed to
remove tissue autofluorescence background.
data over a wide enough range of glucose levels). Then the subject was given a
standard glucose solution drink widely used in the clinics for OGTT (75 g glucose,
Trutol, Thermo Scientific). Over the course of 2 to 3 hours, Raman spectra were
collected every 5 minutes from the thenar skin fold in transmission mode (830 nm
laser at 100 mW, 1 minute acquisition). Concurrently, blood glucose measurements
were taken by finger-sticks every 10 minutes. All clinical study protocols involving
human subjects were conducted after receiving approval by the MIT Committee On
the Use of Humans and Experimental Subjects (COUHES).
6.3 Results and discussion
6.3.1 Tissue autofluorescence removal
A typical set of Raman spectra collected from the human subjects is shown in Fig.
6-4. In this figure, it can be seen that the raw Raman spectra shown on the left panel
have a slowly varying background arising from tissue autofluorescence. This tissue
autofluorescence interferes with glucose detection in two ways:
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Figure 6-5: PLS calibration performed on clinical Raman spectroscopy and blood
glucose concentration data. Leave-one-out cross-validation was performed by devel-
oping a calibration model on all but one pair of Raman spectrum and corresponding
reference blood glucose concentration. The developed model was then tested on the
remaining data pair. This procedure was repeated until all combinations were ex-
hausted.
1. The tissue autofluorescence raises the overall intensity of the spectra, thereby
increasing the CCD shot noise.
2. The tissue autofluorescence undergoes time-dependent fluorescence photobleach-
ing, which may falsely correlate with time-dependent changes in glucose levels.
These detrimental effects of tissue autofluorescence photobleaching on blood analyte
detection had been studied previously by Barman, Kong and co-workers [36]. In order
to remove the autofluorescence background, the Raman spectra were processed with
a modified low-order polynomial curve-fitting technique developed by Lieber et al.
[38]. The result of this "Lieber-fitting" step is shown on the right panel of Fig. 6-4.
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6.3.2 Calibration model development
The calibration model was developed using partial least squares (PLS) technique. As
mentioned previously, PLS is a linear regression technique that obtains a regression
vector which relates the Raman spectrum to the corresponding reference glucose
concentration with the maximum amount of sensitivity (Fig. 6-5).
In addition, a non-linear regression technique based on support vector machine
(SVM) was used as suggested by a recent study which demonstrated improvements
in blood analyte detection accuracy over conventional PLS regression [39]. These
improvements may be due to non-linear and non-glucose specific variations in the
Raman spectra such as those arising from tissue turbidity variations, which could
adversely affect conventional linear regression techniques [39]. In brief, unlike PLS
and other least squares regression techniques that use a quadratic loss function to
assign penalty to data points lying farther away from the regression points, SVR uses
an even more sensitive non-quadratic loss function in order to enhance robustness in
regression against spurious outliers [100]. In order to implement SVM-based regres-
sion (SVR), a computer code library developed by Chang and Lin [101] was used to
perform calibration and prediction on the clinical Raman spectra and blood glucose
concentrations.
Finally, for each spectroscopic calibration method, the dynamic concentration cor-
rection (DCC) scheme described in Chapter 3 was used to see if calibration accuracy
can be improved by correcting for the lag between blood and interstitial fluid glucose
concentrations. In the following sections, the calibration and prediction algorithm
performance was tested by applying increasingly rigorous tests.
6.3.3 Verification of calibration
Raman spectra of the thenar skin fold and the corresponding finger-stick blood glucose
measurements were obtained from 18 human subjects during 28 separate OGTT ses-
sions (730 data points). As described later, some human subjects underwent multiple
OGTT sessions on different days in order to test for prospective prediction perfor-
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mance. The relationship between the clinical Raman spectroscopy and blood glucose
concentration data were extracted by applying four different calibration methods:
1. PLS regression on raw Raman spectra
2. PLS regression on Raman spectra with autofluorescence removed
3. SVR on raw Raman spectra
4. SVR on Raman spectra with autofluorescence removed
In addition, these calibration methods were repeated with DCC implementation. In
order to observe the calibration and prediction performance, the results were plotted
on a Clarke error grid (Fig. 6-6), which is an analysis tool widely used in the diabetic
research community to characterize the performance of a glucose sensing device [102].
The regions labeled in the Clarke error grid have the following clinically significant
implications:
e Region A: Estimated values within 20% of the reference value. Ideally, all data
points should lie in this region.
* Region B: Estimated values outside of 20% but would not lead to inappropriate
treatment.
* Region C: Data points in this region may lead to unnecessary treatment.
* Region D: Data points indicating dangerous failure to detect hypoglycemia or
hyperglycemia.
e Region E: Data points leading to wrong diagnosis and leading to inappropriate
treatment of hypoglycemia or hyperglycemia that can worsen the condition.
The U.S. Food and Drug Administration (FDA) specifies a minimum requirement for
all glucose sensing devices that greater than 95% of the data points should lie in the A
or B regions in order for them to be permitted for clinical use. However, for practical
clinical applications, the FDA also specifies a desirable performance guideline of a
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maximum error of 15% error for glucose levels less than 75 mg/dl and a maximum of
20% error for levels greater than 75 mg/dl. Similarly, the International Organization
for Standardization (ISO) requires a maximum error of 15 mg/dl error for glucose
levels less than 75 mg/dl and a maximum of 20% error for levels greater than 75
mg/dl.§ In Fig. 6-6, these guidelines corresponded to the region delimited by the
dotted lines for glucose levels less than 75 mg/dl, and the "A" region for glucose
levels greater than 75 mg/dl.
More recently, Parkes et al. suggested an alternative to the existing Clarke error
grid. Named "Consensus Error Grid", or sometimes alternatively called "Parkes
Error Grid", this new error grid was based on the consensus of 100 endocrinologists
in a survey conducted to grade the clinical risk and importance of the regions of the
estimated vs. reference glucose concentration plot [104]. In contrast, the Clarke error
grid was developed by much smaller number of clinicians, and it has been criticized
by some researchers for the discontinuities in the clinical risk boundaries [105, 106].
More glucose sensor manufacturers have recently started to use this new error grid
over the conventional Clarke error grid, and it remains to be seen whether the new
error grid will officially replace the conventional Clarke error grid.
For each calibration method, an initial verification was done by performing calibra-
tion using all the data points within the OGTT data set, and predicting on each data
point within the same data set ("leave-none-out" cross validation, Fig. 6-6). Since
the calibrated algorithm is predicting on its own calibration data, the leave-none-out
cross validation is essentially a self-fit. In Figs. 6-6 and 6-7, the corresponding data
points on the Clarke error grid lie very close to the 45 degree line (with R2 close to
one) for all calibration methods, indicating a good calibration based on these data
sets. However, these results reveal little about the prediction performance, as the
calibrated algorithms should by definition reflect the features of the calibration data
set.
§As of 2010, these guidelines are being reviewed by the FDA for a more stringent requirement of
10 or 15% maximum error [103].
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Figure 6-6: Leave-none-out cross validation. Verification of calibration by self-
predicting on the calibration data (18 human subjects, 28 OGTTs, 730 data points).
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Figure 6-7: Leave-none-out cross validation, with DCC. Verification of calibration
with DCC by self-predicting on the calibration data (18 human subjects, 28 OGTTs,
730 data points).
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Figure 6-8: Time course of glucose concentrations measured during an
tolerance test, as measured by conventional finger-prick glucometer (o)
spectroscopy via leave-one-out cross validation (x).
oral glucose
and Raman
6.3.4 Leave-one-out cross validation
For a more rigorous verification of calibration, leave-one-out cross-validation was per-
formed on the data set for each calibration method. In this procedure, all but one
set of Raman spectrum and corresponding reference blood glucose concentration were
used to perform the calibration. The regression vector produced as a result of this
calibration step was then tested by predicting on the remaining Raman spectrum and
blood glucose concentration data pair. This procedure was repeated by selecting an-
other data pair to be left out, until all combinations were exhausted. While the data
sets involved are all from the same OGTT session, such leave-one-out cross-validation
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procedure is prospective in nature, as the data set used for prediction is not included
in the calibration data set.
Figure 6-8 shows the time course of glucose concentrations measured during an
oral glucose tolerance test for one human subject, as measured by conventional finger-
prick glucometer (o) and Raman spectroscopy via leave-one-out cross validation (x).
In this figure, it can bee seen that conventional PLS regression on the raw Raman
spectra performed the worst, while better performance was observed with SVR, where
the glucose concentrations measured by the glucometer matched closely with those
estimated by Raman spectroscopy. This data set, however, was from only one human
subject.
A more complete view of the performance comparisons can be seen in the Clarke
error grid of Fig. 6-9, which summarizes the results of leave-one-out cross-validation
performed on 18 human subjects, during 28 OGTT sessions (730 data points). In this
figure, it can be seen that SVR tends to improve cross validation accuracy compared
with the corresponding PLS regression methods. An initial assessment on 11 hu-
man subjects seemed to indicate an apparent improvement in calibration accuracy by
autofluorescence removal. However, upon completion of the analysis of all 18 human
subject data, applying autofluorescence removal by Lieber-fitting did not improve the
calibration accuracy for either PLS or SVR. In fact, it slightly increased the cross val-
idation errors, making the PLS calibration with Lieber-fitting to have the worst cross
validation performance. This suggests that subtracting the low order polynomial to
remove autofluorescence may have actually had negative effects on the calibration
accuracy by introducing undesirable spectral distortions. It also suggests that there
is little or no spurious correlation between autofluorescence photobleaching and glu-
cose concentrations during these OGTT protocols, which all exhibited non-monotonic
rise and fall in glucose levels in contrast to the autofluorescence intensity variation
by photobleaching which is typically a monotonic exponential decay. However, the
effect of autofluorescence background removal may become more significant when the
calibration algorithm is used prospectively on different OGTT data sets, which may
have a much higher or lower autofluorescence intensities.
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Figure 6-9: Leave-one-out cross-validation performed on clinical Raman spectra and
blood glucose concentrations collected from 18 human subjects (28 OGTTs, 730 data
points).
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For all four calibration methods, 100% of the data points were in the "A" or "B"
region, more than satisfying the minimum FDA requirement for clinical application.
In addition, for all four calibration methods, over 90% of the data points were in the
"A" region and satisfied the target guidelines of both FDA and ISO. In particular,
for the case of SVR calibration on raw Raman spectra, 97% of the data points were
in the "A" region (with RMSEP of 12.13 mg/dl) and satisfied the target guidelines
of both FDA and ISO.
Finally, the same calibration methods were repeated with DCC implementation
(Fig. 6-10). In this figure, the order of performance of the four calibration methods
were the same as that of Fig. 6-10, with little change in cross-validation errors.
This may be due to the fact that, unlike the forearm or the abdominal skin, the
palmar thenar skin is relatively well-vascularized by a mesh of capillary vessels [107].
In fact, for these 18 subjects, the optimal lag time constant a as estimated by the
DCC PLS calibration process had a mean value of 1.9 min (standard deviation of
0.16 min) which is much shorter than that observed in the forearm and abdominal
skin (around 10 minutes). This suggests that implementation of DCC could have
different results depending on the degree of vascularization of the specific anatomical
site. Furthermore, Thennadil et al. suggested that the observed lag time cited in the
literature involving electrochemical sensors may be partly due to the lag contributed
by the sensor itself, as they have observed much shorter lag in glucose concentrations
when measured by direct interstitial fluid aspiration from the forearm and dorsal
hand skin [108]. As such, the cited lag time of about 10 minutes as measured by
electrochemical interstitial fluid sensors may require further verification by using an
interstitial fluid aspiration study as described by Thennadil et al [108].
6.3.5 Prospective prediction on different days
For practical non-invasive glucose monitoring, the device should require only a one-
time or infrequent calibration sessions for successful glucose predictions in subsequent
measurements. The leave-one-out cross validations performed in the previous section
only demonstrate glucose measurement ability within the same OGTT calibration
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Figure 6-10:
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Leave-one-out cross-validation with DCC performed on clinical Ra-
and blood glucose concentrations collected from 18 human subjects (28
data points).
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Figure 6-11: Prospective prediction performed on one human subject. Calibration
performed on one set of OGTT data was used to predict on another set of OGTT
data obtained from the same subject on a different day.
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Figure 6-12: Prospective prediction performed with DCC on one human subject.
Calibration performed with DCC on one set of OGTT data was used to predict on
another set of OGTT data obtained from the same subject on a different day. (The
same data set as the previous figure.)
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session, or in different OGTT sessions with exactly identical measurement conditions.
While these conditions are applicable for a miniaturized and wearable device which
consistently measures Raman spectra from exactly the same location, the size of
present prototype require reattachment of the device to the skin fold for each separate
OGTT session, which presented difficulties in prospective predictions. In this section,
the skin Raman spectra and blood glucose concentration data from the same human
subjects are analyzed over multiple OGTT sessions in order to test for the prospective
prediction performance of the calibration methods. Out of the 18 human subjects,
5 subjects were asked to participate in more than one OGTT sessions. The results
of prospective prediction on one such subject is shown in Figs. 6-11 and 6-12. In
Fig. 6-11, one data point in the case of PLS regression on raw Raman spectra was
in the "C" region, while the rest of the data points as well as those of the other
calibration methods were in the clinically acceptable "A" or "B" regions. While
these satisfied the minimum FDA requirement for clinical use, the data points for the
SVM based regression formed a flat horizontal line, which clearly indicated the failure
to show sensitivity to glucose variations. This suggests that although SVM based
regression showed superior cross-validation results within the same OGTT session,
it was not flexible enough to be carried over to another OGTT session. Specifically,
the calibration by SVM based regression was done on a hyperplane at which the
prospective Raman spectra did not have any significant glucose-specific variations.
This could also be interpreted as a form of "overfitting". On the other hand, the PLS
regression based methods were able to transfer some of their glucose sensitivity to
another OGTT session (Fig. 6-11), albeit with significant degradation in performance
compared with leave-one-out cross validation. In Fig. 6-12, implementation of DCC
slightly reduced the prediction error for the case of PLS regression on raw spectra
while leaving other cases largely unaffected.
Similar prospective prediction was performed on the remaining four human sub-
jects to produce Fig. 6-13, where a total of five human subjects underwent multiple
OGTT sessions on 2 to 5 different days. In these subjects, prospective prediction by
SVM based calibration methods again produced series of flat horizontal lines indicat-
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ing lack of glucose sensitivity. On the other hand, the PLS based calibration methods
showed better glucose sensitivity which somewhat improved with DCC implementa-
tion (Fig. 6-14), although many data points were in clinically undesirable "C" and
"E" regions. This shows that a higher accuracy in leave-one-out cross validation
within the same OGTT session does not necessarily translates to a better prospective
prediction performance. In particular, while SVM based calibration provides smaller
cross validation error by capturing the subtle non-linearities ignored by conventional
PLS regression methods, it becomes less robust against non-glucose specific variations
in prospective validations.
The difficulty in prospective prediction across multiple days is thought to arise
mainly from the inability to reproduce exactly the same measurement conditions.
Although spectral measurements can be made from approximately the same skin
location, the multi-layered and heterogeneous nature of the skin tissue causes differ-
ences in the acquired Raman spectra unless collected at exactly the same angle and
pressure. For this reason, even during the same OGTT session, a brief disruption
due to the human subject's request to remove his or her hand from the device (e.g.
to stretch or to use the rest room) was enough to significantly alter the spectral fea-
tures and reduce the calibration accuracy. This suggests that a glucose monitoring
device that uses Raman spectroscopy would perform the best when developed in a
miniaturized and wearable form (e.g. like a watch or a ring) so that the device can
be fixed on the skin surface and maintain its position relative to the skin tissue once
a calibration session has been performed.
6.4 Conclusion
This study has used a portable clinical Raman spectroscopy instrument to collect
Raman spectra from human subjects undergoing OGTT. The Raman spectra were
collected from the thenar skin folds in transmission mode, using a non-imaging optic
(CHC) for enhanced throughput. The study has also demonstrated that, within
the same OGTT session with the CHC fixed on the same location on the skin, the
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Figure 6-13: Prospective prediction performed on 5 human subjects. For each human
subject, calibration performed on one set of OGTT data was used to predict on other
sets of OGTT data obtained from the same subject on 2 to 5 different days.
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Figure 6-14: Prospective prediction performed with DCC on 5 human subjects. For
each human subject, calibration performed on one set of OGTT data was used to
predict on other sets of OGTT data obtained from the same subject on 2 to 5 different
days. (The same data set as the previous figure.)
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Raman spectroscopy instrument can measure glucose levels in a non-invasive manner
while also satisfying the requirements and guidelines specified by the FDA and ISO.
Finally, the study has revealed potential difficulty in prospective prediction on the
same individual due to significant changes in the measurement site and conditions
on different days. It has also shown that advanced non-linear regression techniques
such as SVR should be approached with caution, as a calibration algorithm highly
tailored to a particular calibration data set may become more vulnerable to non-
glucose specific variations in prospective Raman spectra collected under different
conditions. This problem may be alleviated by a precise control of skin measurement
site and conditions by using a micro-manipulator and a pressure transducer, or by
developing a miniaturized and wearable Raman glucose monitoring device which can
be fixed on the same skin location with little change in measurement conditions.
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Chapter 7
Conclusion and future directions
7.1 Review of objectives and accomplishments
7.1.1 Address the issue of lag between blood and ISF glucose
concentrations
In Chapter 3, the lag between blood and ISF glucose concentrations has been studied
in detail. It has been noted that this lag between the two compartments during rapid
changes in glucose levels could lead to calibration errors, arising from the inconsisten-
cies between the Raman spectra (which probe the ISF glucose) and the reference blood
glucose concentration. In addition, a solution to this problem has been presented by
introducing the DCC algorithm, where the ISF and blood glucose concentrations
were inter-converted using a first order diffusion model, based on the estimation of
the direction and rate of change in glucose levels observed in two separate measure-
ments. The validity of this model was confirmed by performing numerical simulations
based on real blood and ISF glucose values measured during glucose clamping pro-
cedures. Finally, the uncertainty in the predicted glucose concentration was derived
and quantified for both conventional and DCC-based calibration algorithms.
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7.1.2 Design and construct a high-throughput and portable
clinical Raman spectroscopy system
While the objectives of achieving high throughput and maintaining compact physi-
cal dimensions initially seemed conflicting, both goals were achieved by introducing
the CHC for collecting Raman spectra in transmission mode. By converting back-
scattered collection geometry to transmission mode, the excitation source was no
longer on the same side as the collection fibers and significant improvement in optical
fiber packing fraction (and thereby throughput) could be achieved. In addition, the
CHC and its matching lens were designed to achieve the same performance as a very
long CPC while maintaining much smaller physical dimensions.
7.1.3 Demonstrate clinical feasibility through human subject
studies
The clinical instrument described in Chapter 5 was used successfully for collecting
Raman spectra from human subjects undergoing OGTT. In Chapter 6, the Raman
spectra and the blood glucose concentrations were used to develop a calibration
model by both conventional PLS regression as well as nonlinear support vector re-
gression techniques, which were both in turn performed on raw Raman spectra and
autofluorescence-removed Raman spectra. Analyzing the calibration and leave-one-
out cross-validation results showed that all four combinations performed better than
the minimum requirements of FDA, while the best cross-validation performance was
observed for the case of support vector regression (SVR) performed on raw spectra.
However, prospective prediction on the same individual on a separate OGTT session
conducted on a different day was less successful. It also revealed that while SVR
had the lowest cross-validation errors, it was less robust against changes in measure-
ment conditions compared with conventional PLS regression. Advanced non-linear
regression techniques such as SVR should be approached with caution, as a calibra-
tion algorithm highly tailored to a particular calibration data set may become more
vulnerable to non-glucose specific variations in prospective Raman spectra collected
132
under different conditions. This problem may be alleviated by a precise control of
skin measurement site and conditions by using a micro-manipulator and a pressure
transducer.
7.2 Future directions
Although this study has successfully demonstrated transdermal glucose measurement
by Raman spectroscopy using calibration models developed from the same individual
during the same OGTT session, prospective prediction on a different day was less
successful. Moreover, transferring the calibration model across different individuals
is even more difficult, due to person-to-person variations in skin tissue composition.
However, the ability to non-invasively detect glucose concentration on the same in-
dividual after an invasive calibration session still provides tremendous benefits, as
it can significantly reduce the total number of required figure-sticks. The current
alternative would always require finger pricking or a subcutaneous glucose sensor im-
plant. A future study could repeat the protocol outlined in this thesis with a much
more rigorous control over measurement conditions, by employing micrometers and
pressure transducers. A significant improvement in prospective prediction with the
help of more rigorous control of measurement conditions would provide further confi-
dence in the ability to measure glucose concentrations non-invasively from the same
individual.
While a significant reduction in physical size has been achieved compared to the
laboratory-based setup by developing a portable clinical Raman spectroscopy system,
it is still far from being a hand-held device, which would be ideal for continuous
glucose monitoring. Despite the invasive nature of implanting a needle-shaped sensor
under the skin, the Medtronic Minimed and Abott Lab's FreeStyle Navigator could
still be commercialized due to their small size. Therefore, the next goal would be
to further reduce the size and complexity of the Raman spectroscopy instrument
to bring the technology closer to practical use in the clinic. This would allow for
the development of a miniaturized and wearable Raman glucose monitoring device,
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which can be fixed on the same skin location with little change in measurement
conditions to provide better prospective predictions. Studies are currently under
way to identify the specific spectral wavenumbers that are most crucial for glucose
detection. Successful identification of a small subset of spectral wavenumbers would
enable the replacement of the bulky spectrograph and CCD with smaller and simpler
optical filters and photodetectors.
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Appendix A
List of abbreviations
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Table A.1: List of abbreviations I
Abbreviation
a
ANSI
AR
b
CBG
CISF
CCD
CHC
CNC
COUHES
CPC
CR
CRC
db
DCC
Ac.,
7
FDA
FlagRaman
9
HLA
ISO
ISF
km
ku
yPa
PRaman
is
Meaning
Effective glucose lag time constant
American national standards institute
Anti-reflection
Regression vector
Blood glucose concentration
ISF glucose concentration
Charge-coupled device
Compound hyperbolic concentrator
Computer numerical control
Committee on the use of humans as test subjects
Compound parabolic concentrator
Constrained regularization
Clinical research center
Distance to next boundary in multi-layer tissue simulation
Dynamic concentration correction
Uncertainty in concentration due to spectral overlap and noise
Spectral overlap (non-orthogonality) factor
US food and drug administration
Boolean value indicating if Raman scattering event has ocurred
Anisotropy factor
Hybrid linear analysis
International organization for standardization
Interstitial fluid
Glucose mass transfer coefficient (cm/s)
Rate of glucose uptake by cells (s-1)
Absorption coefficient (cm 1 )
Raman scattering coefficient (cm- 1)
Scattering coefficient (cm-1)
Continued on the next page...
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Table A.2: List of abbreviations II
Abbreviation
MIR
NA
NADH
NAD(P)H
NIH
NIR
OGTT
PCDCC
PLS
PPDCC
RMSECV
RMSEP
S
o-
SNR
SORS
SVM
SVR
Omax
Meaning
Mid-infrared
Numerical aperture
Reduced nicotinamide adenine dinucleotide
Reduced nicotinamide adenine dinucleotide phosphate
National institutes of health
Near infrared
Oral glucose tolerance test
Pre-calibration dynamic concentration correction
Partial least squares
Post-prediction dynamic concentration correction
Root mean squared error of cross validation
Root mean squared error of prediction
Matrix of Raman spectra
Magnitude of noise in the Raman spectrum
Signal to noise ratio
Spatially offset Raman spectroscopy
Support vector machine
Support vector regression
Maximum collimation half angle
Random number uniformly distributed from 0 to 1
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Appendix B
Optical fiber bundle for
CHC-based transmission mode
Raman spectroscopy setup
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Appendix C
Selected relevant MATLAB codes
used in the analysis
141
1 % Determine CPC length
2
3 function L = cpclength (acceptance-angle-degrees, input-radius)
4 L = input-radius.*(1+...
5 sind(acceptance.angle-degrees)) ./tand (accept an ce.angle..degrees) . ..
6 . /sind (accept ance-angleadegrees);
7 end
1 % Draw CPC length vs angles
2
3 acceptance-angle-degrees = [0.1:0.01:30];
4 input-radius = 2;
5 L = cpclength (acceptance-angle.degrees, input-radius);
6 figure;
7 semilogy (acceptance-angleadegrees,L, 'LineWidth' ,2)
s xlabel ('\fontsize{l2}\bf Maximum half angle (degrees)')
9 ylabel ('\fontsize{12}\bf CPC Length (mm)')
10 title (strcat(['\fontsize{l2}\bf CPC Length at ',
num2str(input-radius), ' mm minor aperture radius']))
n1 theta = 3.9
12 syms r;
13 index = find(eval(strcat(['round(acceptance-angle-degrees*100)/100 .
== ',num2str(theta)])));
14 z = L(index);
15 MaxLength = z
16 a = input-radius;
17 C = cosd (theta);
18 S = sind (theta);
19 P = 1+S;
20 Q = 1+P;
21 T = 1+Q;
22 cpc = C * r + 2 * ( C*S *z + a*P )*r + ( z^2 * S^2 - 2*a*C*Q*z - a^2 .
* P*T );
23 large-aperture-radius = eval(solve (cpc))
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1 % CHC design tool
2
3 function [xal,yal,fxal,fyal,xbl,ybl,fxbl,fybl,
4 r-input-aperture, r-output-aperture,acceptance-angle] ...
5 = CHC(a,b,xmax,ymax,rotation-angle)
6 [xal,yal,fxal,fyal,xa2,ya2,fxa2,fya2] =
hyperbola(a,b,xmax,ymax, rotation-angle, 0,0);
7 [xbl,ybl,fxbl,fybl,xb2,yb2,fxb2,fyb2] = ...
hyperbola(a,b,xmax,ymax,-180-rotation-angle, 0,0);
8
9 %% shift in x-direction to align foci
10 [xal,yal] = turn(xal,yal,0,-fxal,0);
ii [xa2,ya2] = turn(xa2,ya2,0,-fxal,0);
12 [fxa2,fya2] = turn(fxa2,fya2,0,-fxal,0);
13 [fxal,fyal] = turn(fxal,fyal,0,-fxal,0);
14 [xbl,ybl] = turn(xbl,ybl,0,-fxbl,0);
15 [xb2,yb2] = turn(xb2,yb2,0,-fxbl, 0);
16 [fxb2,fyb2] = turn(fxb2,fyb2,0,-fxbl,0);
17 [fxbl,fybl] = turn(fxbl,fybl,0,-fxbl, 0);
18
19 %% determine how much to shift in y-direction to have foci aligned
20 [zero, origin-index] = min (abs(xal));
21 yal-offset = -(((yal(origin-index)-fybl) ^2)0.5)/2;
22 ybl-offset = -yal-offset;
23
24 %% shift in y-direction to align foci
25 [xal,yal] = turn(xa1,yal,0,-fxal,yal-offset);
26 [xa2,ya2] = turn(xa2,ya2,0,-fxal,yal-offset);
27 [fxa2,fya2] = turn(fxa2,fya2,0,-fxal,yal-offset);
28 [fxal,fyal] = turn(fxal,fyal,O,-fxa1,yal-offset);
29 [xbl,ybl] = turn(xbl,ybl,0,-fxb1,ybl-offset);
3o [xb2,yb2] = turn(xb2,yb2,0,-fxb1,ybl-offset);
31 [fxb2,fyb2] = turn (fxb2, fyb2,0,-fxbl,ybloffset);
32 [fxbl,fybl] = turn(fxbl,fybl,0,-fxb1,ybl-offset);
33
34 %% Measure CHC length
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35 index-limit = max(find (xal < fxa2));
36 slope = (fyb2 - fyal) / (fxb2 - fxal);
37 extreme-rayl = slope.*xal(1:index-limit) + fyal;
38 slope = (fybl - fya2) / (fxbl - fxa2);
39 extreme-ray2 = slope.*xal(1:index-limit) + fybl;
40 [zero, length-index-a] = min(abs(extreme-xayl - yal(l:index-limit)));
41 [zero, length-index-b] = min(abs(extreme-ray2 - ybl(l:index-limit)));
42 edge-xa = xal(length-index-a);
43 edge-ya = yal(length-index-a);
44 edge-xb = edge-xa;
45 edge-yb = -edge-ya;
46 CHC-length = abs(edge-xa);
47
48 %% Measure aperture
49 r-input-aperture = fyal;
5o r-output-aperture = abs(edge-ya);
51
52 %% Determine acceptance angle
53 output-center = [edge-xa, 0];
54 slope = (fyb2 - output-center(2)) / (fxb2 - output-center(l));
55 acceptance-angle-linel = slope.*xal(1:index-limit) -
slope*output-center (1);
56 slope = (fya2 - output-center(2)) / (fxa2 - output-center(1));
57 acceptance-angle-line2 = slope.*xal (1: index-limit) -
slope*output-center (1);
58 acceptance-angle = atand((fyb2 - output-center(2))/(fxa2 -
output-center(1)));
59 f = abs(fxb2 - output-center(1)); % focal length of lens
60
61 %% Draw figure
62 figure;hold on;plot(xal, yal);plot(xa2, ya2, ':'); % hyperbola ...
conjugate pair al and a2
63 plot([fxal fxa2],[fyal fya2],'.');line([fxal fxa2], [fyal
fya2], 'LineStyle',':') % conjugate foci fal and fa2
64 plot(xbl, ybl, 'r');plot(xb2, yb2, ':r'); % hyperbola conjugate ...
pair bl and b2
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65 plot([fxbl fxb2],[fybl fyb2],'.r'); line([fxbl fxb2],[fybl ...
fyb2],'Color','r','LineStyle',':'); % conjugate foci fb1 and fb2
66 line([fxal fxbl],[fyal fybl],'Color','k') % input aperture
67 plot (xal (1:index-limit), extreme-rayl, ...
' :k'I) ;plot (xa1 (1: index Ilimit) , ext reme-ray2, ':k);
68 plot ([edge-xa edgexb], [edge-ya edge-yb], '.k'); % output aperture
69 line( [edge-xa edge-xb], [edge-ya edge-yb], 'Color', 'k')
70 plot (xal (1:index-limit), acceptance-angle-line1, ...
':m') ;plot(xal(1:index-limit), acceptance-angle-line2, ':m');
71 title({['Inputs: A=', num2str(a), ', B=', num2str(b), ',
\theta-r-o-t=',num2str(rotation-angle), 'deg :'];
72 ['R-i=',num2str(r-input-aperture),'mm', ',
R-o=',num2str(r-output-aperture), 'mm', ',
73 L=',num2str(CHC-length),'mm',', ...
\theta-a-c-p-t=',num2str(acceptance-angle), 'deg',',
f=',num2str(f), 'mm'1})
74 axis([-xmax xmax -ymax ymax]) % specify axis limits
75 xlabel('x (mm)')
76 ylabel('y (mm)')
1 % Form hyperbola with set rotation angle and offset
2
3 function [xlout,ylout, fxlout,fylout, x2out,y2out, fx2out,fy2out] =
hyperbola(a,b,xmax, ymax, rotation-angle, xoffset,yoffset)
4
s % Program to plot the hyperbola
6 % y^2/a^2 - x^2/b^2 = 1
7 x = linspace(-xmax,xmax,1001);
8 y=sqrt(((x.^2)./(b^2)+1).*a^2); % corresponding y values
9 xl = x; yl = Y;
10 x2 = x; y2 = -y;
11
12 %% foci
13 fxl = 0;
14 fyi = sqrt(a.^2+b.^2);
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15 fx2 = 0;
16 fy2 = -(sqrt(a.^2+b.^2));
17
18 %% Rotation
19 [xlout,ylout] = turn(xl,yl,rotation-angle,xoffset,yoffset);
20 [x2out,y2out] = turn(x2,y2,rotation-angle,xoffset,yoffset);
21 [fxlout,fylout] = turn(fxl,fyl,rotation-angle,xoffset,yoffset);
22 [fx2out,fy2out] = turn(fx2,fy2,rotation-angle,xoffset,yoffset);
i function [xout,yout] = turn(xin,yin,theta,x-offset,y-offset)
2
3 % Program to rotate and translate x,y values from x",y" to x,y space.
4 % theta value in degrees.
5
6 % rotation matrix
7 xfm = [cosd(theta) sind(theta); ...
8 -sind(theta) cosd(theta)];
9 % make x,y values into a column vector
10 r-in = [xin; yin];
11 % rotate
12 r-out = xfm*r-in;
13 x = rout(1,:); y = r-out(2,:);
14 xout = x + x-offset;
15 yout = y + y-offset;
1 %% Perform OGTT data analysis
2 loaddata_20110119
3 low-glucose = round(min(c) - 10);
4 highaglucose round(max(c) + 10);
5
6 % PLS Raw Data
7 pred-title-pls = 'PLS Raw Data';
8
9 % Collapse: Take the mean of all frames
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mean-spectra = [];
for q=l:datapoints
if n(q)<10
zerolabel =
elseif (10<n(q)
zerolabel =
'_00 ';
&& n(q)<100)
-O' ;
else
zerolabel = '-';
end
mean-spectra = [mean-spectra; eval((strcat('mean (',dataname,
zerolabel, num2str(n(q)), ''')')))]; % Raw
eval(strcat(['clear ', datanamel, zerolabel, num2str(n(q))));
end
figure;plot (mean-spectra', 'LineWidth', 0.5);
%% Leave one out cross validation)
[raw-datapoints, raw-pixels] = size (mean-spectra);
mean-spectra-sub = mean-spectra -
(min(mean-spectra')) '*(ones(raw-pixels,1))';
scale-factor = ones (raw-pixels, 1) *max (mean-spectra-sub');
mean-spectra-scaled = mean-spectra-sub ./ scale-factor' ; % scale
0 to 1
figure;plot (mean-spectra-scaled');
Preds = candp(mean-spectra-scaled,c,20,100,1340,, [ ], [1:size(c,1)]);
figure;rp-raw=rplot(c,Preds);
% lvl = input('# of loading vectors?
lvl=5;
predpls = Preds(:,lvl+l);
[b, w, v, MeanA, MeanC] = ...
plscaliback(mean-spectra-scaled(:,100:1 3 4 0), c, lvl+l); %%%%%
b-pls-raw = b;
w-pls-raw = w;
v-pls-raw = v;
MeanA-raw = MeanA;
pred-pls = nonneg(pred-pls);
R2.pls = (corr (c, pred-pls))^2
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42 rmsep-pls=rmsep (predpls, c)
43 plot-prediction (c,pred-pls, R2-pls, rmsep-pls, pred-title-pls, ...
time.step, datapoints, low-glucose, high-glucose)
44
45 %% PLS Lieber Fit
46 predtitle-lieber = 'PLS Lieber Fit';
47
48 % Truncated and Lieber-fit Background removed
49 mean-spectra-lieber = [;
50 for i=l:datapoints
51 mean-spectra-lieber = [mean-spectra-lieber; ...
lieberfit(mean-spectra(i,180:840), 5, 500)];
52 end
sa [lieber-datapoints, lieber..pixels] = size (mean-spectra-lieber);
54 scale-factor = ones(lieber-pixels, 1) *max(mean-spectra-lieber');
5s mean-spectra-lieber-scaled mean-spectra-lieber ./ scale-factor'
% scale : 0 to 1
56 figure; plot (mean-spectra-lieber-scaled');
57 % PLS analysis (Leave one out cross validation)
58 Preds..lieber = candp (mean-spectra-lieber-scaled, c, 20, 1, 661, 1,
], [1:size(c,1)]);
59 figure; rp-raw-lieber=rplot (c, Preds-lieber);
6o %lv2 = input('# of loading vectors?
61 lv2=5;
62 pred-lieber = Preds-lieber(:,lv2+1);
63 [b, w, v, MeanA, MeanC] = plscalib-ck(mean.spectra.lieber-scaled, c,
lv2+1); %%%%%
64 b-pls-lieber = b
65 w.pls-lieber = w;
66 v.pls.lieber = v;
67 MeanA-lieber = MeanA;
68 pred-lieber = nonneg(pred-lieber);
69 R2_lieber = (corr (c, pred-lieber))^2
7o rmsep-lieber = rmsep(pred.lieber,c)
71 plot..prediction (c,pred-lieber, R2.lieber, rmsep-lieber, ...
pred-title-lieber, time..step, ...
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72 datapoints, low-glucose, high..glucose)
73
74 %% SVM Raw
75 predtitle-svm.raw = 'SVM Raw'
76 libsvm-format (c, mean-spectrascaled, 'svmraw.txt')
77 [ty-raw, tx-raw] = libsvmread (' svm-raw .txt');
78 % Leave one out cross validation
79 p-svm-raw = zeros(datapoints,1);
so for i=l:datapoints
81 if i==1
82 LOO-spectra = tx-raw(2:datapoints,:);
83 LOO-c = c(2:datapoints);
84 else
85 LOO-spectra = [tx-raw(1:i-1, :);tx-raw(i+1:datapoints,:)];
86 LOO-c = [c(1:i-1); c(i+1:datapoints)];
87 end
as m-raw = svmtrain(LOO-c, LOO-spectra, '-s 3 -c 1048576.0 -g
0.00238106 -p 0.000195312');
89 p-svm-r aw (i) = svmpredict (c (i), tx..raw (i,:), m-raw);
90 end
91 rmsep-svm..raw = ((p-svm-raw-c)'*(p-svm..raw-c) /datapoints)^0.5
92 R2-svm-raw = (corr (c, p..svm-raw))^2
93 rmsep-svm-raw = rmsep(p.svm-raw,c)
94 plot..prediction (c,p-svm..raw, R2_svm..raw, rmsep-svm-raw, ...
pred..title-svm-raw, time..step, ...
95 datapoints, low..glucose, high.glucose)
96
97 %% SVM Lieber
98 pred-title-svm-lieber = 'SVM Lieber';
99 libsvmformat (c, mean-spectra.lieber-scaled, 'svm-lieber.txt')
100 [ty, tx] = libsvmread('svm-lieber.txt');
101 % Leave one out cross validation
102 p-svm-lieber = zeros (datapoints, 1);
103 for i=l:datapoints
104 if i==1
105 LOO-spectra = tx(2:datapoints,:);
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106 LOO-c = c(2:datapoints);
107 else
108 LOO-spectra = [tx(1:i-l,:);tx(i+1:datapoints,:)];
109 LOO-c = [c(1:i-1); c(i+1:datapoints)];
110 end
il m-lieber = svmtrain(LOO-c, LOO..spectra, '-s 3 -c 1048576.0 -g ...
0.0012 -p 0.0717936');
112 p..svm-lieber (i) = svmpredict (c (i), tx (i,:), m-lieber);
113 end
114 rmsep-svm-lieber = ((p-svm-lieber-c) '* (p-svm-lieber-c) /datapoints) ^0.5
115 R2-svm-lieber = (corr (c, p-svm-lieber))^2
116 rmsep-svm-lieber = rmsep(p-svm-lieber, c)
117 plot-prediction (c,p-svm-lieber, R2_svm-lieber, rmsep-sm...lieber, ...
pred-title.svm-lieber, time.step, ...
118 datapoints, low-glucose, high-glucose)
119
120 %% DCC PLS Raw
121 [alpha-opt.raw, LV.model-opt, b-model-opt, c-ISF-calib-trans-opt] =
dcc-pls-calib (mean-spectra-scaled, . . .
122 100, 1340, t, c, 0.1);
123 b-dcc-pls-raw = b-model.opt;
124 pred-title-dcc.pls = 'DCC PLS Raw';
125 p-dcc-pls = zeros (datapoints, 1);
126 for i=1:datapoints
127 if i==1
128 LOO-spectra = mean-spectra.scaled(2:datapoints,:);
129 LOO-c = c(2:datapoints);
130 LOO-t = t(2:datapoints);
131 else
132 LOO-spectra =
[mean-spectra-scaled(1:i-1, :);mean-spectra-scaled(i+1:datapoints,:)];
133 LOO-c = [c(1:i-1); c(i+1:datapoints)];
134 LOO..t = [t(1:i-1); t(i+1:datapoints)];
135 end
136 [alpha-opt-raw-LOO, LV-model-opt-LOO, b-model-opt-LOO, ...
c-ISF-calib-trans-opt-LOO] = ...
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137 dcc-pls-calib (LOO-spectra, 100, 1340, LOO.t, LOO-c, 0.2);
138 if i==1
139 p-dcc-pls(i) = c(1);
140 else
141 p..dcc..pls (i) = dcc...pls.predict (mean-spectra-scaled(i-1:i,:),
100, 1340, LOO-spectra, . . .
142 b-model..opt-LOO, alpha-opt.raw-LOO, c-ISF-calib-trans-opt...LOO, ..
t (i-1:i) );
143 end
144 end
145 rmsep-dcc-pls = ((p-dcc.pls-c) '* (p...dcc...pls-c) /datapoints) ^ 0.5;
146 R2-dcc-pls = (corr (c, p...dcc-pls))^2
147 plot-prediction (c,p-dcc-pls, R2-dcc..pls, rmsep..dcc-pls, ...
pred.title..dcc-pls, time..step, ...
148 datapoints, low..glucose, high-glucose)
149
iso %% DCC PLS Lieber Fit
151 [z,1] = size(mean.spectra-lieber-scaled);
152 [alpha-opt-lieber, LV-model-opt.lieber, b-model-opt..lieber, ...
c-ISF-calib-trans-opt-lieber] = ...
153 dcc..pls-calib(mean.spectra.lieber-scaled, 1, 1, t, c, 0.1);
154 b.dcc-pls-lieber = b.model-opt.lieber; %%%%%
i55 pred-title.dcc.pls-lieber = 'DCC PLS Lieber Fit';
156 p-dcc.pls.lieber = zeros (datapoints, 1);
157 for i=1:datapoints
158 if i==1
159 LOO-spectra = mean..spectra-lieberr-scaled(2:datapoints,:);
160 LOO...c = c(2:datapoints);
161 LOO-t = t(2:datapoints);
162 else
163 LOO...spectra = [mean-spectra-lieber-scaled(1:i-1,:);
164 mean...spectra-lieber.scaled (i+1: datapoints,:)];
165 LOO-c = [c(1:i-1); c(i+1:datapoints)];
166 LOO-t = [t(1:i-1); t(i+1:datapoints)];
167 end
168 [alpha-opt-lieber.LOO, LV-model-opt-LOO, b-model.opt-LOO, ...
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c.ISF-calib.trans..opt-lieber-LOO] = ...
169 dcc-pls-calib(LOO...spectra, 1, 661, LOO-t, LOOc, 0.2);
170 if i==1
171 p-dcc.pls-lieber(i) = c(1);
172 else
173 p-dcc-pls-lieber(i) =
dcc..pls-predict (mean.spectra-lieber-scaled(i-1:i,:), 1, 661,
LOO...spectra, . . .
174 b-model-opt-LOO, alpha-opt-lieber-LOO, ...
cISF-calib-trans-opt-lieberLOO, t (i-1:i));
175 end
176 end
177 rmsep-dcc..pls-lieber =
((p-dcc-pls-lieber-c) '*(p-dcc-pls-lieber-c)/datapoints)^0.5;
178 R2_dccpls-lieber = (corr (c, p-dccxpls.lieber)) ^2
179 plot-prediction (c,p-dcc-pls.lieber, R2_dcc-pls-lieber, ...
rmsep-dccpls-lieber, pred-title-dcc.pls..lieber, ...
180 time..step, datapoints, low.glucose, high-glucose)
181
182 %% DCC SVM Raw
183 pred-title-dcc.svm-raw = 'DCC SVM Raw'
184 libsvm-format (c-ISF..calib-trans-opt, mean.spectra-scaled, ...
' svmdcc...raw. txt')
185 [ty..dcc..raw, tx.dcc-raw] = libsvmread('svm-dcc-raw.txt');
186
187 %% Leave one out cross validation
188 p.isfdcc.svm-raw = zeros (datapoints, 1);
189 for i=l:datapoints
190 if i==l
191 LOO-spectra = tx-dcc-raw(2:datapoints,:);
192 LOO..c = cISF-calib...trans-opt (2:datapoints);
193 else
194 LOO-spectra =
[tx-dcc-raw(1:i-1, :);tx-dcc-raw(i+1:datapoints,:)];
195 LOO-c = [cISF.calib..trans.opt(1:i-1); .. .
c..ISF-calib-trans-opt (i+1:datapoints) ] ;
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196 end
197 m-dcc-raw = svmtrain(LOO-c, LOO-spectra, '-s 3 -c 1048576 -g ...
10.73213196615 -p 0.0018223300616');
198 p-isf..dcc-svm-raw (i) = svmpredict (c-ISF-calib-t rans-.opt (i), ...
tx-dcc-raw(i,:), m-dcc-raw);
199 end
200 % 1048576.0, g=7.46426393229, p=0.0018223300616
201 p-dcc-svm-raw = p-isf -dcc-sm-raw (2: end) + . . .
alpha-opt-raw*diff(p-isf-dcc-sm-raw) . /diff(t);
202 p..ccc...svm...raw = [c (1); p.dcc-svm-raw];
203 rmsep-dcc.svm..raw = ...
( (p..dcc-svm-raw-c) '* (p-dcc-svm-raw-c) /datapoints) ^0. 5
204 R2..dcc..svm-raw = (corr (c, p-dcc-svm-raw)) ^2
205 plot.prediction (c, p-dcc-svm..raw, R2-dcc-svm-raw, rmsep-dcc-svm.raw, ...
pred-title-dcc..sm-raw, time-step, ...
206 datapoints, low-glucose, high-glucose)
207
208 %% DCC SVM Lieber
209 pred-title-dcc-svm-lieber = 'DCC SVM Lieber'
210 libsvm-format (c-ISF-calib-trans-opt, mean-spectra-lieber-scaled, ...
'svm-dcc-lieber. txt')
211 [ty-dcc-liber, tx...dcc.lieber] = libsvmread('svm.dcc-lieber.txt');
212
213 %% Leave one out cross validation
214 p-isf-dcc..svm-lieber = zeros (datapoints,1);
215 for i=l:datapoints
216 if i==1
217 LOO-spectra = tx-dcc-lieber(2:datapoints,:);
218 LOO..c = c-ISF-calib.trans-opt (2:datapoints);
219 else
220 LOO..spectra =
[tx-dcc-lieber(1:i-1, :);tx-dcc-lieber(i+1:datapoints,:)];
221 LOO-c = [c-ISF.calib-trans-opt(1:i-1); .. .
c-ISF-calib-trans-opt (i+1:datapoints) I;
222 end
223 m.dcc-lieber = svmtrain(LOO-c, LOO.spectra, '-s 3 -c 1048576.0 ...
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-g 42.8 -p 0.00023683');
224 p-isf..dcc-svm-lieber (i) = svmpredict (c-ISF-calib-trans-opt (i), ...
tx..dcc-lieber (i,:), m-dcc-lieber);
225 end
226 p-dcc.svm..lieber = p-isf -dcc-svm-lieber (2:end) +
alpha-opt-lieber*diff (p..isf..dcc-svm-lieber) . /diff (t);
227 p..dccC..svm-1ieber = [c(l) ;p..dcc..vm.ieber];
228 rmsep.dcc..svm-lieber = ...
((p-dcc-svm-lieber-c)'*(p-dcc-svm-lieber-c)/datapoints)^0.5
229 R2-dcc-svm-lieber = (corr (c, p-dcc..svm-lieber))^2
230 plot-prediction (c,p.dcc-svm-lieber, R2..dcc..svm-lieber,
rmsep-dccsvm-lieber, pred-title.dcc..svm-lieber, ...
231 time-step, datapoints, low-glucose, high-glucose)
1 function[b, w, v, MeanA, MeanC] = PLSCALIBCK(Spectra, Concs, LoadNum)
2
3 % Modified by Chae-Ryon Kong from PLSCALIB
4 % Spectra is the matrix of spectral values as they are to be used
5 % by the routine. Each spectrum occupies one ROW (horizontal ...
direction).
6 % Concs are the concentrations of the prediction analyte in each sample.
7 % LoadNum is the number of loading vectors to use.
8 %
9 % Output:
10 % w is the matrix of weight vectors, with each COLUMN one vector.
11 % b is the matrix of loading vectors, " " " " "
12 % v is a column vector of score coefficients.
13 % MeanA is the average spectrum.
14 % MeanC is the average concentration.
15
16 w=[]; b=[]; v=[]; MeanA=[]; MeanC=[]; tt=[];
17
18 %STEP 1: PREPROCESSING
19 MeanA=mean (Spectra);
20 A = Spectra- ones(size(Spectra,1), 1)*MeanA;
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21 MeanC=mean(Concs);
22 c = Concs-MeanC;
23 h=1;
24
25 %LOOP
26 while (h<LoadNum)
27 %STEP 2: FORM WEIGHT VECTOR AND NORMALIZE IT
28 x=(A'*c)/(c'*c);
29 w=[w,x/sqrt(x'*x)];
30 %STEP 3: FORM LATENT SCORE VECTOR
31 t=A*w(:,h);
32 %compute sum of squares here, since it's used twice later
33 tt=t'*t;
34 %STEP 4: RELATE SCORE VECTOR TO CONCENTRATIONS
35 v=[v;(t'*c)/tt];
36 %STEP 5: FORM B, THE PLS LOADING VECTOR
37 b=[b, ((A'*t)/tt)];
3 %STEP 6: CALCULATE RESIDUALS
39 A=A-t*b(:,h)';
40 c=c-v(h)*t;
41 %STEP 7: INCREMENT AND LOOP BACK
42 h=h+1;
43 end;
1 function c=PLSPREDJCK(Spectra, LoadNum, w, b, v, MeanA, MeanC)
2 % Modified by Chae-Ryon Kong from PLSPRED
3 % Spectra is a matrix of prediction spectra, with each spectrum
4 % occupying one ROW.
5 % LoadNum is the maximum number of loading vectors to use.
6
7 %Output:
8 % c : concentration predictions.
9 % The nth column is the predictions achieved using n-1 ..
loading vectors
10 % (the first column is the average concentration of the ..
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calibration set).
11
12 %STEP 1: PREPROCESSING
13 NumofSpectra=size(Spectra,1);
14 A = Spectra- ones(NumofSpectra, 1)*MeanA;
15 c = ones(NumofSpectra,1)*MeanC;
16 h=1;
17
18 %LOOP
19 while (hsLoadNum)
20
21 %STEP 2: CALCULATE SCORE VECTOR
22 t=A*w(:,h);
23
24 %STEP 3: UPDATE CONCENTRATION PREDICTIONS
25 % add to the previous column
26 c=[c, c(:,h) + t*v(h)];
27
28 %STEP 4: CREATE RESIDUAL
29 A=A-t*(b(:,h))';
30
31 %STEP 5: LOOP BACK
32 h=h+l;
33 end;
1 %% Load OGTT data for 01-19-2011
2 concs = load ('concs_20110119.txt');
3 filename = 'Thenar_1sec-60fr';
4 dataname = 'Thenar_20110119';
5 time-step = 5;
6 frames = 60;
7 remove-datapoint = 0; % *** Remove one data point for missing ...
spectrum. 0 for none.
8 t-r = concs(:,1);
9 c-r = concs(:,2);
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10 t = interp(t-r,2);
11 % c = interp(c-r,2);
12 c = interp1 (t-r, c-r, t, 'linear', 'extrap');
13 c = c(1:end-1);
14 t = t(l:end-1);
15 datapoints = size(c,1);
16 n=O:time-step: (datapoints-1)*time-step; % starting from 0
17 n=n(:);
18 % n=time-step:time-step:datapoints*time-step % not starting from 0
19 if (remove-datapoint == 1)
20 t = [t(2:datapoints)];
21 c = [c(2:datapoints)];
22 n = [n(2:datapoints)];
23 elseif (remove.datapoint > 1)
24 t = [t(1:removeadatapoint-1);t(removecdatapoint+1:datapoints)];
25 c = [c(1:remove-datapoint-1);c(remove-datapoint+1:datapoints)];
26 n = [n(1:removeadatapoint-1);n(removeadatapoint+1:datapoints)];
27 end
28 datapoints = size(c,1);
29 figure; plot (t,c, 'o');
30 set(gca, 'fontsize', 14)
31 set(findobj('Type', 'line'), 'LineWidth', 2)
32 axis([0 time-step*datapoints 80 230])
33 xlabel ('Time (min)', 'fontsize', 14, 'fontweight', 'bold')
a ylabel ('Glucose (mg/dl)', 'fontsize', 14, 'fontweight', 'bold')
35 title ('Glucometer Readings','fontsize', 16, 'fontweight', 'bold')
36
37 %% cosmic ray removal and extracting frames
38 for q=1:datapoints
39 if n(q)<10
40 zerolabel = '_00';
41 elseif (10sn(q) && n(q)<100)
42 zerolabel = '-O';
43 else
4 zerolabel = '-';
45 end
157
eval(strcat(['load ', filename], zerolabel, num2str(n(q)), '.txt;')
eval(strcat(dataname, zerolabel, num2str(n(q)), ' =
for k=l:frames
eval(strcat(dataname, zerolabel, num2str(n(q)), ' = [',
dataname, zerolabel, num2str(n(q)), ', cosmic-remove(',
filename,zerolabel, num2str(n(q)), ...
'(',num2str(1+1340*(k-1)), ':', num2str(1340*k), ',4))];'));
end
eval(strcat(['clear ', filename], zerolabel, num2str(n(q))))
% Remove cosmic rays and hot pixel artifacts
function [output] = cosmic-remove (raw-spectrum, varargin)
% function[output] = cosmic-remove (rawspectrum, thresh)
% output = output spectrum with cosmic rays removed
% thresh (Optional) = minimum spike height to be treated as cosmic ray
% (default: thresh = 1000)
raw-spectrum = raw-spectrum (:);
output = raw-spectrum;
L-s = length (raw-spectrum);
filtered = medfiltl(raw-spectrum,15);
spikes = raw-spectrum - filtered;
if (length (varargin) == 1)
threshold = varargin{1};
else
threshold = 1500;
end
ind = [];
ind = find(abs(spikes)>threshold);
L = length(ind);
if (L==O)
return
else
for i=l:L
output (ind(i)) = filtered (ind(i));
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50
51
52 end
)
if (ind(i)>3)
output (ind(i)-3)
output (ind(i)-2)
output (ind(i)-1)
end
if (ind(i)>2)
output (ind(i)-2)
output (ind(i)-1)
end
if (ind(i)==2)
output (ind(i)-1)
end
if (ind(i)<(Ls-2))
output (ind(i)+1)
output (ind(i)+2)
output (ind(i)+2)
end
if (ind(i)<(L-s-1))
output (ind(i)+1)
output (ind(i)+2)
= filtered
= filtered
= filtered
= filtered
= filtered
(ind(i)-3);
(ind(i)-2);
(ind(i)-1);
(ind i)-2);
(ind(i)-1);
= filtered (ind(i)-l);
= filtered
= filtered
= filtered
= filtered
= filtered
(ind(i)+1);
(ind(i)+2);
(ind(i)+2);
(ind(i)+1);
(ind(i)+2);
end
if (ind(i)<L-s)
output (ind(i)+1) = filtered (ind(i)+l);
end
end
end
function [vector] = nonneg(vector)
L = length (vector)
for k=1:L
if (vector(k)<O)
vector(k) = 0;
end
8 end
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1 function [I = plot-prediction (c,predval, R2, rmsep-val,
predLtitle, time-step, datapoints, low, high)
2 % [] = plot-prediction (c,pred-val, R2, rmsep-val, pred-title)
3 figure;h=plot([time-step:time-step:time-step*datapoints], pred-val, ...
'X', [time-step:time-step:time-step*datapoints], c, 'o',
'MarkerSize', 10, 'linewidth', 2);
4 legend('Predicted', 'Glucometer');
5 set(gca, 'fontsize', 14) ;
6 axis([0 time-step*datapoints low high])
7 xlabel ('Time (min)', 'fontsize', 14, 'fontweight', 'bold')
8 ylabel ('Glucose (mg/dl)', 'fontsize', 14, 'fontweight', 'bold')
9 title (pred-title,'fontsize', 16, 'fontweight', 'bold')
10 figure; [A, B] =egamagdl(c, predval);title ([predLtitle,', R^2=',
num2str(R2), ' RMSEP=', num2str(rmsepval),'mg/dl'], 'fontsize',
14, 'fontweight', 'bold')
1 function [total, percentage] = ega-mgdl(y,yp)
2 % Plot Clarke Error Grid and perform analysis
3 % [total, percentage] = ega-mgdl(y,yp)
4 %
5 % Inputs:
6 % y = reference values (mg/dl)
7 % yp = predicted/estimtated values (mg/dl)
8 %
9 % Outputs:
10 % total = total points per zone:
11 % total(1) = zone A,
12 % total(2) = zone B, and so on
13 % percentage = percentage of data which fell in certain region:
14 % percentage(1) = zone A,
15 % percentage(2) = zone B, and so on.
16 %
17 % Modified by Chae-Ryon Kong from original code by
18 % Edgar Guevara Codina
19 % codina@REMOVETHIScactus. iico. uaslp. mx
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20 % ...
21 % Error checking
22 if nargin==O
23 error('clarke:Inputs','There are no inputs.')
24 end
25 if length(yp) # length(y)
26 error('clarke:Inputs','Vectors y and yp must be the same length.')
27 end
28 % if (max(y) > 400) (max(yp) > 400) (min(y) < 0) (min(yp) < 0)
29 % error('clarke:Inputs','Vectors y and yp are not in the ...
physiological range of glucose (<400mg/dl).')
30 % end
31 % Determine Screen Size ...
32 scrsz = get(0,'ScreenSize')-[0 -5 0 72];
% Determine data length ...
3 n = length(y);
35 % Plot Clarke's Error Grid ...
36 h =
plot(y,yp,'ko','MarkerSize',4,'MarkerFaceColor','b','MarkerEdgeColor','b');
37 xlabel('Reference Glucose (mg/dl)','fontsize', 14, 'fontweight',
'bold');
38 ylabel('Predicted Glucose (mg/dl)','fontsize', 14, 'fontweight', ...
'bold');
39 title('Clarke Error Grid','fontsize', 14, 'fontweight', 'bold');
40 set(gca,'XLim',[0 400],'fontsize', 14);
41 set(gca,'YLim',[0 400],'fontsize', 14);
42 axis square
43 hold on
44 plot([0 400], [0 400],'k-') % Theoretical 45 degree ...
regression line
45 plot([0 70/1.2],[70 70],'r-', 'linewidth',2)
46 plot([70/1.2 400/1.2], [70 400], 'r-', 'linewidth',2)
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plot([70 70], [70*1.2 400],'k-', 'linewidth',2)
plot([0 70],[180 180],'k-', 'linewidth',2)
plot([70 290], [180 400],'k-', 'linewidth',2)
Corrected upper B-C boundary
plot([70 70],[0 70*0.8],'r-', 'linewidth',2)
plot([70 400], [70*0.8 320],'r-', 'linewidth',2)
plot([180 180], [0 70],'k-', 'linewidth',2)
plot([180 400], [70 70],'k-', 'linewidth',2)
plot([240 240], [70 180],'k-', 'linewidth',2)
plot([240 400], [180 180],'k-', 'linewidth',2)
plot([130 180],[0 70],'k-', 'linewidth',2)
B-C boundary slope OK
text(30,20,'A','fontsize',14,'fontweight', 'bol
text(30,150,'D','fontsize',14,'fontweight', 'bo
text(30,380,'E','fontsize',14,'fontweight', 'bo
text(150,380,'C','fontsize',14,'fontweight', 'b
text(160,20,'C','fontsize',14,'fontweight', 'bo
text(380,20,'E','fontsize',14,'fontweight', 'bo
text(380,120,'D','fontsize',14,'fontweight', 'b
text(380,260, 'B', 'fontsize',14, 'fontweight', 'b
text(280,380,'B','fontsize',14,'fontweight', 'b
set(gcf, 'color', 'white'); % S
total = zeros(5,1); % I
percentage = zeros(5,1); % I
for i=1:n,
if (yp(i) s 70 && y(i) s 70) (yp(i) s 1.
0.8*y(i))
total(1) = total(1) + 1; % Z
else
if ( (y(i) 180) && (yp(i) s 70)
yp(i) > 180 )
total(5) = total(5) + 1;
% ...
% Lower ...
d');
Id');
ld');
old');
ld');
ld');
old');
old');
old');
ets the color to white
nitializes output
nitializes output
2*y(i) && yp(i) > ...
one A
|| ( (y(i) < 70) && ...
% Zone E
else
if ((y(i) 70 && y(i) 290) && (yp(i) > y(i) + 110) ) ..
| ((y(i) > 130 && y(i) s 180)&& (yp(i) < ( 7 /5)*y(i) ...
- 182))
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total(3) = total(3) + 1; % Zone C
else
if ((y(i) > 240) && ((yp(i) > 70) && (yp(i) < 180)))
11 (y(i) < 70/1.2 && (yp(i) s 180) && (yp(i) >
70)) || ((y(i) > 70/1.2 && y(i) < 70) && (yp(i)
> 1.2*y(i)))
80 total(4)
81 else
82 total (2)
83 end
end
85 end
86 end
87 end
88 percentage = (total./n)*100;
89 % ...
= total(4) + 1;% Zone D
= total(2) + 1;% Zone B
% End of 4th if
% End of 3rd if
% End of 2nd if
% End of 1st if
% End of for loop
function [] = libsvmnformat (Y, spectralamatrix, out-filename)
% Convert data into format compatible with LIBSVM and write to file
% libsvmformat (Y, spectral-matrix, out-filename)
% Output File Format:
% Y index-1: x-1 index-2: x_2 ... \n
[nurndatapoints, nurupixels] = size(spectralamatrix);
fid = fopen(out-filename, 'w');
for a = 1:num-datapoints
fprintf(fid, '%6.2f ', Y(a));
for b = 1:num-pixels
fprintf(fid, '%u:%-8.2f ', b, full(spectralamatrix(a,b)));
end
fprintf(fid, '\n');
end
fclose(fid);
163
1 % dcc-pls-calib
2 % CALIBRATION step using BG and spectroscopic data
3 %
4 % Inputs:
5 % Raman-calib : Calibration Raman spectra (rows, pixels)
s % minpix, maxpix : pixel range
7 % t : time (min)
8 % cBG-calib : Calibration Blood glucose vector
9 % step : time step for iteration (min)
10 %
11 % Outputs:
12 % alpha-opt : optimized time constant (min)
13 % LV-model-opt : optimized number of PLS loading vectors for DCC
14 % b-model-opt optimized PLS regression b vector for DCC
15 % c-ISF-calib-trans-opt : ISF glucose converted from blood glucose
16
17 function [alpha-opt, LV-model-opt, b-model-opt, ...
c-ISF-calib.trans-opt I = dcc...pls.calib (Raman-calib,
18 minpix, maxpix, t, c-BG-calib, step)
19 rmsecv.default = 10^5;
20 rmsecv-.nin = rmsecv-default;
21 alpha-opt = 0; % assign initial value
22 LV-no-model-opt = 0; % assign initial value
23 LV-model.opt = 0; % assign initial value
24 b-no-model-opt = [];
25 b-model-opt = [];
26 LV-rnax = 10; % maximum number of loading vectors over which to iterate
27 count-alpha = 0;
28 calib..size = size(c-BG-calib, 1);
29 c-ISF-calib-trans = c-BG-calib(1)*ones(calib..size,1); % ...
initializing the cISF-calib-trans variable
so c-ISF-calib.trans..opt = c-ISF.calib...trans; % initializing the ...
c-ISF-calib-trans-opt variable
31 c-BG-cv-trans = c-BG-calib(1)*ones(calib-size,1);
32
33 for alpha = 1:step:10
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34 count-alpha = count-alpha+1;
35 % Performing the BG to ISF transform so that the regression ...
model is fully based on ISF glucose
36 for i = 1:1:calib..size-1
37 cBG-avg = 1/2*(cBG-calib(i) + c-BG-calib(i+1));
38 % assumption is that the value of the BG at the middle of the time ...
interval is the average of the values at the end-points
39 c-ISF-calib-trans(i+1) = ...
cISF-calib-trans(i)*exp(-(/alpha)*(t(i+1)-t(i))) +
1/(6*alpha)*(t(i+1)-t(i))*(cBG-calib(i)*exp(-/alpha*(t(i+1)-t(i)))
+ c-BG-calib(i+1) + ...
4*cBG-avg*exp(-1/(2*alpha)*(t(i+1)-t(i))));
40 end
41 % Performing PLS leave-one-out cross-validation on ...
(c-ISF-calib..trans, Raman-calib) to obtain the RMSECV ...
corresponding to different sets of (alpha, LV)
42 R-raw=candp (Raman-calib, c.ISF-calib-trans, LV...max, minpix, maxpix, 1, [ ...
], [1: size (c.ISF-calib...trans, 1)]);
43
44 for i = 1:LV-max+l;
45 c...BG..cv-trans (2: end) = R-raw (2: end, i) +
alpha*diff(R-raw(:,i))./diff(t); % convert R-raw-ISF ...
back to BG before comparing rmsecv
46 rmsecv-temp(i) = rmsep(c-BG-cvtrans, c.BG-calib); % ...
convert R-raw-ISF back to BG before comparing rmsecv
47 rmsecv.-plot (count -alpha, i) = rmsecv.temp(i);
48 end
49 [rmsecv.dyn, LV] = min(rmsecv-temp);
so if (LV<3)
51 LV=3;
52 end
53 % Determing the optimal alpha and LV
54 if (rmsecv..dyn-rmsecv..min<O)
55 rmsecv.min = rmsecv-dyn
56 alpha-opt = alpha;
57 LV-model-opt = LV;
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58 c.ISF-calib-trans-opt = c-ISF-calib-trans;
59 end
6o end
61
62 plscalib(Ramancalib(:,minpix:maxpix), cISF-calib-trans.opt, LVmax);
63 b-model-opt = bvector(LV-model-opt-1);
1 % dcc-pls-predict
2 % PREDICTION step using b-vectors and prediction Raman spectra
3 %
4 % Inputs:
5 % Raman-pred Prediction Raman spectra (rows, pixels)
6 % b-model-opt optimized PLS regression b vector for DCC
7 % alpha-opt : optimized time constant (min)
8 % cISF-calib-trans-opt : ISF glucose converted from blood glucose
9 % dt : data time step (e.g. 2.485 min)
10 % Outputs:
11 % cBG-model-pred: blood glucose concentration predicted with DCC
12
13 function [c...BG...model.pred] = dcc-pls-predict(Raman-pred, minpix,
maxpix, ...
14 Raman-calib, b-model-opt, alpha.opt, cISF-calib..trans-opt, t)
15
16 % DYNAMIC MODEL PREDICTION: INPUTS OF b-model-opt AND PREDICTION ...
RAMAN SPECTRA
17 cISF-model-pred =
(Raman-pred (:, minpix:maxpix)--ones (size (Ramanpred, 1) , 1) * ...
18 mean (Raman-calib(:,minpix:maxpix) ) ) *b..model-opt+mean (c.ISF.calibtrans.opt);
19 % c-ISF-model-pred = ...
(Raman-pred (:, minpix:maxpix) -ones (size (Raman.pred, 1) , 1)*
20 mean (Raman..pred (: , minpix:maxpix) ) ) *b.model.opt+mean (cISF-ca lib-t ran s-opt);
21 c-BG..model.pred.temp = cISF..modelpred(2: end) + ...
alpha-opt*diff (c.ISF-model.pred) ./diff (t); . ..
22 % Predicting cBG based on alpha-opt from calibration
23 cBG-model-pred = c.BG-model-pred-temp;
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